On this page
Quick Reference
Overview and Recommendations
Background
- •DKA is a metabolic emergency caused by absolute or relative insulin deficiency, resulting in hyperglycemia (typically >250 mg/dL), ketosis (β-hydroxybutyrate >3.0 mmol/L), and metabolic acidosis (pH <7.3, bicarbonate <15 mEq/L). The condition occurs when insulin deficiency triggers uncontrolled lipolysis and ketogenesis.
- •Type 1 diabetes accounts for the majority of DKA cases, but type 2 diabetes patients can develop DKA during severe stress, illness, or with certain medications. can cause euglycemic DKA where glucose levels may be normal or only mildly elevated.
- •Common precipitants include infection (most common), medication non-adherence, new-onset diabetes, cardiovascular events, and psychological stress. Up to 30% of cases occur at initial diabetes diagnosis, particularly in children under 2 years who have the highest risk of severe presentation.
- •Mortality ranges from 1-5% in developed countries but remains higher in resource-limited settings. Complications include cerebral edema (particularly in children), cardiovascular collapse, acute kidney injury, and electrolyte disturbances.
- •The classic triad of polyuria, polydipsia, and weight loss may be preceded by nausea, vomiting, abdominal pain, and altered mental status. Kussmaul respirations (deep, rapid breathing) represent compensatory hyperventilation for metabolic acidosis.
Evaluation
- •Suspect DKA in any patient with diabetes presenting with nausea, vomiting, abdominal pain, or altered mental status. Maintain high suspicion in patients taking even with normal glucose levels (euglycemic DKA).
- •Obtain immediate point-of-care glucose and ketones (blood ketones preferred over urine). Blood glucose >250 mg/dL with ketones >1.5 mmol/L strongly suggests DKA, but euglycemic variants exist.
- •Order arterial blood gas immediately - pH <7.3 with anion gap >12 mEq/L confirms metabolic acidosis. Calculate anion gap: [Na+] - ([Cl-] + [HCO3-]). Normal anion gap is 8-12 mEq/L.
- •Assess severity using pH and bicarbonate: mild DKA (pH 7.25-7.30, HCO3- 15-18 mEq/L), moderate DKA (pH 7.0-7.24, HCO3- 10-14 mEq/L), severe DKA (pH <7.0, HCO3- <10 mEq/L). Severe DKA requires ICU admission.
- •Evaluate hemodynamic status carefully - patients often present with significant dehydration and may have hypotension (systolic BP <90 mmHg). Assess for signs of shock including tachycardia, poor capillary refill, and altered mental status.
- •Perform comprehensive metabolic panel including electrolytes, BUN, creatinine, and phosphorus. Check serum osmolality if concerned for concurrent . Obtain CBC to evaluate for infection or hemoconcentration.
- •Assess neurological status using Glasgow Coma Scale and examine for signs of cerebral edema (headache, altered mental status, focal deficits). Children and young adults have highest risk for this life-threatening complication.
- •Identify precipitating factors through history and examination: recent illness, medication changes, insulin omission, new stressors. Obtain cultures (blood, urine) if infection suspected. Consider cardiac evaluation if chest pain or ECG changes present.
- •Monitor for concurrent conditions: (subcutaneous emphysema), (nasal lesions), or other serious infections that may complicate DKA and require immediate intervention.
- •Document baseline vital signs, mental status, and fluid balance for monitoring treatment response. Establish IV access (preferably two large-bore IVs) and consider central access for severe cases or difficult peripheral access.
Management
- •Initiate IV insulin infusion at 0.1 units/kg/hour after confirming serum potassium >3.3 mEq/L. Do not give insulin bolus routinely as it provides no additional benefit and increases hypoglycemia risk.
- •Begin fluid resuscitation with 15-20 mL/kg IV bolus over first hour. Balanced crystalloids are superior to normal saline, reducing time to DKA resolution and preventing hyperchloremic acidosis.
- •Administer early basal insulin (glargine 0.3 units/kg subcutaneously) within 3 hours of diagnosis. This intervention reduces DKA resolution time from 10.2 to 6.8 hours and decreases rebound hyperglycemia.
- •Replace potassium aggressively: if K+ 3.3-5.2 mEq/L, add 20-30 mEq KCl per liter of IV fluid. If K+ <3.3 mEq/L, hold insulin until corrected and give 40 mEq KCl. Monitor every 2 hours initially.
- •Switch to dextrose-containing fluids (D5 lactated Ringer's) when glucose falls below 250 mg/dL to prevent hypoglycemia while continuing insulin to clear ketones. Reduce insulin infusion to 0.05 units/kg/hour at this point.
- •Monitor glucose, electrolytes, and anion gap every 2 hours initially. Target glucose decline of 50-75 mg/dL per hour. Maintain glucose 150-250 mg/dL during active treatment to allow continued ketone clearance.
- •Avoid sodium bicarbonate unless pH <6.9, as it increases cerebral edema risk and delays ketone clearance. When indicated, give 100 mEq in 400 mL sterile water over 2 hours.
- •Continue treatment until DKA resolution: anion gap <12 mEq/L, bicarbonate >15 mEq/L, pH >7.30, and ketones <0.6 mmol/L. Patient must also be alert and able to tolerate oral intake.
- •Transition to subcutaneous insulin when resolution criteria met: calculate total daily dose (0.5-0.8 units/kg/day), give 50% as basal and 50% as prandial insulin. Continue IV insulin for 1-2 hours after first subcutaneous dose.
- •Admit severe DKA (pH <7.1) to ICU. Mild-moderate DKA can be managed on medical floors with appropriate protocols. Consider subcutaneous insulin protocols (SQuID) for mild DKA in stable patients.
- •Identify and treat precipitating factors: start antibiotics for suspected infection, review medication adherence, address psychosocial stressors. Discontinue if present.
- •Provide diabetes education before discharge: sick day management, ketone monitoring, when to seek care, medication adherence. Arrange endocrinology follow-up within 1-2 weeks and ensure access to glucose/ketone monitoring supplies.
- •Monitor for complications: cerebral edema (especially in children), acute kidney injury, cardiac arrhythmias from electrolyte shifts, and treatment-related hypoglycemia or hypokalemia.
- •Consider continuous glucose monitoring initiation before discharge to reduce future DKA risk. Patients with recurrent DKA benefit from diabetes technology and intensive management programs.
Board Review — High Yield
- •Euglycemic DKA — occurs with SGLT-2 inhibitors, pregnancy, or starvation; glucose may be normal but ketones and acidosis present
- •Kussmaul respirations — deep, rapid breathing compensating for metabolic acidosis; do not suppress with sedation
- •Cerebral edema — most feared complication in children; presents with headache, altered mental status, bradycardia with hypertension
- •Early basal insulin — glargine 0.3 units/kg within 3 hours reduces DKA resolution time by 3-4 hours
- •Lactated Ringer's superior — to normal saline for DKA; faster anion gap closure and less hyperchloremic acidosis
- •Potassium replacement critical — insulin drives K+ intracellularly; hold insulin if K+ <3.3 mEq/L
- •Bicarbonate contraindicated — unless pH <6.9; increases cerebral edema risk and delays ketone clearance
- •Resolution criteria — anion gap <12, HCO3- >15, pH >7.30, ketones <0.6 mmol/L, alert mental status
- •Insulin transition — continue IV insulin 1-2 hours after first subcutaneous dose to prevent rebound ketosis
Deep Dive — Evidence Details
Recognition and Triage
- ▸Euglycemic DKA occurs in up to 30% of pregnant patients, requiring high clinical suspicion based on ketosis rather than glucose levels alone
- ▸Children under 2 years and overweight children have the highest risk of severe DKA presentation, necessitating immediate critical assessment
- ▸Adult-onset type 1 diabetes is frequently misdiagnosed as type 2 diabetes, leading to delayed recognition and inappropriate initial management
Clinical Presentation Patterns
Diabetic ketoacidosis presents with variable clinical manifestations that require systematic recognition for prompt triage. The classic triad includes polyuria, polydipsia, and weight loss, though presentation varies significantly by age and diabetes type [16]D. In emergency settings, patients may present with altered mental status, dehydration, and Kussmaul respirations [5]C.
Euglycemic DKA occurs in up to 30% of pregnant patients, making recognition particularly challenging as glucose levels may be normal or only mildly elevated [4]. This variant requires high clinical suspicion based on ketosis and acidosis rather than hyperglycemia alone.
Age-Specific Recognition Patterns
Pediatric Presentations
Children under 2 years have the highest risk of presenting with severe DKA at diagnosis [20]D. Younger age is consistently associated with more severe metabolic derangement, with infants often presenting in extremis [11]D[20]D. Overweight children demonstrate worse metabolic presentation with higher rates of severe DKA compared to normal-weight peers [18]D.
Adult Presentations
Adult-onset type 1 diabetes frequently presents with less severe symptoms and may be misdiagnosed as type 2 diabetes [10]D. Adults over 40 years often have atypical presentations that delay recognition and appropriate triage [10]D. Latent autoimmune diabetes in adults (LADA) shares clinical features with type 2 diabetes, leading to frequent misdiagnosis and delayed DKA recognition [12]D.
High-Risk Populations for Delayed Recognition
| Population | Risk Factors | Recognition Challenges |
|---|---|---|
| Pregnant women | Euglycemic DKA (30%) | Normal glucose levels [4] |
| Infants <2 years | Severe presentation | Non-specific symptoms [20]D |
| Adults >40 years | Atypical presentation | Misdiagnosed as T2DM [10]D |
| Overweight children | Worse metabolic state | Delayed symptom recognition [18]D |
| LADA patients | T2DM-like features | Inappropriate initial management [12]D |
Emergency Department Triage Protocols
Immediate Assessment Priorities
Patients presenting with hyperglycemia >600 mg/dL require immediate resuscitation and critical care evaluation [5]C. Hypotension (BP <90 mmHg systolic) and hypothermia indicate severe decompensation requiring emergent intervention [5]C.
Diagnostic Workup Sequence
Blood gas interpretation is critical for rapid DKA confirmation. Emergency physicians demonstrate >90% concordance in recognizing DKA through arterial blood gas analysis, making this the preferred initial diagnostic tool [23]D. Point-of-care ketone measurement should be obtained immediately in suspected cases.
Severity Stratification
Severe DKA presents with pH <7.1 and requires intensive care unit admission [20]D. Bicarbonate <10 mEq/L indicates life-threatening acidosis requiring immediate intervention [23]D. Mental status changes correlate with severity and guide triage decisions.
Screening and Early Identification
Family History Screening
First-degree relatives of type 1 diabetes patients have significantly elevated risk and should undergo autoantibody screening [17]D. In Korean populations, 3.4% of children with type 1 diabetes have affected family members, emphasizing the importance of family history assessment [13]D.
Presymptomatic Detection
Autoantibody screening in high-risk populations enables identification of presymptomatic type 1 diabetes, potentially preventing DKA at diagnosis [3][17]D. The INNODIA screening program demonstrates feasibility of systematic screening in first-degree relatives aged 1-45 years [17]D.
Recognition Barriers and Solutions
Healthcare Provider Education
Structured training curricula significantly improve clinician confidence and knowledge in DKA recognition [24]D. Case-based education aligned with international guidelines enhances diagnostic accuracy in resource-limited settings [24]D.
Artificial Intelligence Support
Large language models demonstrate 80-90% concordance with emergency physicians in DKA diagnosis and management recommendations [22]D[23]D. AI-assisted interpretation may support clinical decision-making, particularly in settings with limited specialist availability.
Special Considerations
COVID-19 Impact
The COVID-19 pandemic has been associated with delayed diabetes diagnosis and increased DKA severity at presentation [20]D[25]C. Uncontrolled diabetes combined with COVID-19 infection creates particularly high risk for rapid deterioration [25]C.
Complications Requiring Immediate Recognition
Necrotizing fasciitis may complicate severe DKA, requiring emergent surgical intervention [5]C. Mucormycosis should be suspected in patients with DKA and nasal lesions or central nervous system symptoms [7]C[25]C. These complications carry extremely high mortality and require immediate recognition and treatment.
Immediate Assessment (ABCs)
- ▸Hypovolemic shock from severe dehydration requires immediate fluid resuscitation with 30 mL/kg normal saline bolus before detailed assessment
- ▸Kussmaul breathing indicates compensatory hyperventilation for metabolic acidosis and should not be suppressed during airway management
- ▸Euglycemic DKA from SGLT2 inhibitors presents diagnostic challenges with normal glucose levels but typical ketoacidosis features
The primary survey in follows standard emergency protocols with specific attention to DKA-related complications. Immediate assessment focuses on identifying and managing life-threatening conditions that require intervention before detailed diagnostic workup.
Airway Assessment
Assess airway patency and protection. Patients with severe DKA may present with altered mental status requiring airway intervention [5]C. Kussmaul breathing (deep, rapid respirations) is a compensatory mechanism for metabolic acidosis and should not be suppressed [38]D. Document respiratory pattern as it indicates acidosis severity.
Intubation considerations include:
- Altered mental status with inability to protect airway [5]C
- Severe acidosis with respiratory fatigue
- Hemodynamic instability requiring aggressive resuscitation
Breathing Evaluation
Evaluate respiratory effort and effectiveness. Kussmaul respirations represent compensatory hyperventilation for metabolic acidosis [38]D. Assess for:
- Respiratory rate and depth
- Oxygen saturation
- Signs of respiratory fatigue
- Chest wall movement symmetry
Document baseline respiratory compensation before any interventions that might alter ventilation.
Circulation Assessment
Hemodynamic Status
DKA patients commonly present with hypovolemic shock due to severe dehydration [29]C[30]C. Initial assessment includes:
- Blood pressure (may show hypotension: BP 67/56 mmHg in severe cases) [5]C
- Heart rate (typically tachycardic)
- Capillary refill time
- Peripheral pulses quality
- Skin temperature and color
Dehydration Severity
Clinical assessment of dehydration in DKA is challenging due to unique pathophysiology [36]D. Physical examination findings associated with dehydration severity include [26]:
- Mucous membrane dryness
- Skin turgor
- Sunken eyes
- Altered mental status
- Peripheral perfusion
Note: Traditional dehydration estimates may be inaccurate in DKA, potentially leading to fluid overadministration [36]D.
Neurological Assessment
Altered mental status ranges from mild confusion to coma [5]C[29]C. Document:
- Glasgow Coma Scale
- Pupillary response
- Focal neurological deficits
- Signs of increased intracranial pressure
Cerebral edema is a life-threatening complication, particularly in pediatric patients [27]. Warning signs include:
- Deteriorating mental status
- Headache
- Vomiting
- Bradycardia with hypertension
Temperature Assessment
Document core temperature. Hypothermia (35.7°C) may indicate severe illness or sepsis [5]C. Fever suggests infectious precipitant requiring immediate antimicrobial therapy.
Immediate Life-Threatening Complications
Shock Management
Severe dehydration can lead to hypovolemic shock requiring immediate intervention [29]C[30]C. Initial resuscitation includes:
- 30 mL/kg normal saline bolus for hemodynamic instability [5]C
- Vasopressor support if fluid-refractory shock
- Central venous access for unstable patients
Concurrent Medical Emergencies
DKA may present with or mask other emergencies:
- Necrotizing fasciitis with subcutaneous emphysema [5]C
- Non-occlusive mesenteric ischemia causing abdominal pain [29]C
- Acute kidney injury from severe dehydration [30]C[36]D
- Infectious precipitants requiring antimicrobial therapy
Special Considerations
Euglycemic DKA
SGLT2 inhibitor-associated euglycemic DKA presents diagnostic challenges with normal or mildly elevated glucose levels [32]D[33]C. Maintain high suspicion in patients taking these medications with:
- Metabolic acidosis
- Elevated ketones
- Typical DKA symptoms
- Recent surgery or illness [43]C
Pediatric Considerations
Children with DKA require careful neurological monitoring due to cerebral edema risk [27]. Avoid aggressive fluid resuscitation unless hemodynamically unstable. Document baseline mental status for comparison during treatment.
Concurrent Conditions
Patients may present with multiple metabolic derangements:
- Hyperosmolar hyperglycemic state overlap [34]C
- Lactic acidosis from metformin or shock [33]C
- Alcohol-related complications in adults [41]D
The primary survey must identify immediately life-threatening conditions requiring intervention before proceeding to secondary assessment and definitive DKA management.
| System | Key Assessment | Critical Findings | Immediate Action |
|---|---|---|---|
| Airway | Patency, protection | Altered mental status | Consider intubation |
| Breathing | Kussmaul respirations | Respiratory fatigue | Support ventilation |
| Circulation | BP, perfusion | Hypotension, shock | 30 mL/kg NS bolus |
| Disability | Mental status, GCS | Coma, focal deficits | Cerebral edema workup |
| Exposure | Temperature, skin | Hypothermia, infection | Warming, antibiotics |
Primary Management Algorithm
- ▸Lactated Ringer's solution is superior to normal saline for DKA fluid resuscitation, achieving faster anion gap closure with reduced complications
- ▸Subcutaneous insulin protocols (SQuID) are safe and effective for mild-to-moderate DKA, reducing ICU utilization by >33% while maintaining equivalent outcomes to IV insulin
Initial Assessment and Stabilization
All patients with DKA require immediate assessment of severity and hemodynamic status. Severe DKA (pH <7.0, bicarbonate <5 mEq/L, or altered mental status) mandates ICU admission [64]D. Mild-to-moderate DKA (pH 7.0-7.3, bicarbonate 5-15 mEq/L) can be managed on medical floors with appropriate protocols [50][56]D[63]D.
Step 1: Fluid Resuscitation
Initial fluid choice: 15-20 mL/kg IV bolus over first hour [52][65]D[66]D. Lactated Ringer's demonstrates superior outcomes compared to normal saline, with faster anion gap closure (median 15.6 vs 18.2 hours) and reduced hyperchloremic acidosis [52][65]D.
Subsequent fluid management:
- Continue lactated Ringer's at 250-500 mL/hr based on hemodynamic status [52]
- Switch to dextrose 5% in lactated Ringer's when glucose falls below 250 mg/dL [63]D
- Target fluid replacement: 50-100 mL/kg over first 24 hours [64]D
Step 2: Insulin Therapy Initiation
Severe DKA: Fixed-rate intravenous insulin infusion (FRIII) 0.1 units/kg/hr [59]D[60]D
Mild-to-moderate DKA: Subcutaneous protocol (SQuID) [50][56]D[63]D:
- Insulin glargine 0.25 units/kg subcutaneously once
- Insulin aspart 0.15 units/kg subcutaneously every 2 hours
- Continue until anion gap <12 mEq/L and bicarbonate >15 mEq/L
Step 3: Insulin Dose Adjustments
IV insulin protocol:
- Reduce FRIII to 0.05 units/kg/hr when glucose falls below 250 mg/dL [60]D
- Target glucose decline: 50-75 mg/dL per hour [59]D
- Maintain glucose 150-250 mg/dL during treatment [59]D
Subcutaneous protocol adjustments:
- Reduce aspart to 0.1 units/kg every 2 hours if glucose <150 mg/dL [63]D
- Administer dextrose 25g IV if glucose <100 mg/dL [63]D
Step 4: Electrolyte Management
Potassium replacement:
- If K+ >5.2 mEq/L: No replacement initially [64]D
- If K+ 3.3-5.2 mEq/L: Add 20-30 mEq KCl per liter of IV fluid [64]D
- If K+ <3.3 mEq/L: Hold insulin until K+ >3.3 mEq/L, give 40 mEq KCl [64]D
Phosphate: Replace if <1.0 mg/dL with 20-30 mEq K-phosphate [64]D
Magnesium: Replace if <1.8 mg/dL with 2g magnesium sulfate IV [64]D
Step 5: Monitoring and Resolution Criteria
Monitor every 2 hours:
- Glucose, electrolytes, anion gap, pH
- Mental status and vital signs
- Urine ketones (if available) [63]D
DKA resolution criteria (all must be met):
- Glucose <200 mg/dL
- Anion gap <12 mEq/L
- Bicarbonate >15 mEq/L or pH >7.30
- Alert mental status [50][63]D
Step 6: Transition to Maintenance Therapy
Subcutaneous insulin transition:
- Start basal insulin 2 hours before discontinuing IV insulin [64]D
- Calculate total daily dose: 0.5-0.8 units/kg/day [64]D
- Give 50% as basal insulin, 50% as meal-time insulin [64]D
Treatment Algorithm Summary
Step 1: Assess severity → ICU if severe, floor if mild-moderate Step 2: Lactated Ringer's 15-20 mL/kg IV bolus Step 3: Insulin therapy (IV 0.1 units/kg/hr for severe; SQuID protocol for mild-moderate) Step 4: Monitor glucose, electrolytes every 2 hours Step 5: Add dextrose when glucose <250 mg/dL Step 6: Reduce insulin rate when glucose <250 mg/dL Step 7: Continue until resolution criteria met Step 8: Transition to subcutaneous insulin 2 hours before stopping IV insulin
Special Considerations
Euglycemic DKA: Requires modified approach with early dextrose administration and ketone-targeted insulin dosing rather than glucose-based adjustments [57]C[58]D. Consider in patients on or .
Pregnancy: Requires more aggressive fluid resuscitation and closer fetal monitoring [48].
| Protocol | Indication | Insulin Dose | Route | Monitoring | Key Advantage | Evidence |
|---|---|---|---|---|---|---|
| IV Insulin (Severe) | pH <7.0, HCO3 <5, AMS | 0.1 units/kg/hr | Intravenous | ICU, q1-2h | Rapid onset | [59]D[60]D |
| SQuID (Mild-Moderate) | pH 7.0-7.3, HCO3 5-15 | Glargine 0.25 + Aspart 0.15 units/kg q2h | Subcutaneous | Floor, q2h | Reduced ICU use | [50][56]D[63]D |
| Reduced IV Rate | Glucose <250 mg/dL | 0.05 units/kg/hr | Intravenous | ICU/Floor, q2h | Prevents hypoglycemia | [60]D |
Pharmacotherapy
- ▸Early basal insulin (0.3 units/kg within 3 hours) reduces DKA resolution time by 3-4 hours compared to IV insulin alone
- ▸Balanced electrolyte solutions are superior to 0.9% saline, reducing resolution time and preventing hyperchloremic acidosis
- ▸Bicarbonate therapy is contraindicated except in severe acidosis (pH <6.9) due to increased cerebral edema risk
Insulin Therapy
First-Line Treatment
Continuous intravenous insulin infusion remains the cornerstone of DKA management [74][75][80][81]. Standard dosing is 0.1 units/kg/hour after an optional loading dose of 0.1 units/kg IV bolus [89]. Low-dose protocols using 0.05 units/kg/hour demonstrate comparable efficacy with reduced hypoglycemia risk in pediatric patients [89].
Early Basal Insulin Administration
Early initiation of long-acting insulin during IV insulin infusion significantly reduces time to DKA resolution [74][75][80][81][82][83]. Insulin glargine 0.3 units/kg subcutaneously administered within 3 hours of diagnosis shortens resolution time from 10.2 hours to 6.8 hours [75][80]. Insulin degludec 0.3 units/kg subcutaneously shows similar efficacy [74]. In pediatric patients, early basal insulin reduces IV insulin duration by 4-6 hours [76][82][83].
NPH insulin represents a cost-effective alternative in resource-limited settings, administered at 0.3 units/kg subcutaneously with comparable outcomes to glargine [86].
Fluid Resuscitation
Crystalloid Selection
Balanced electrolyte solutions (Ringer's lactate, Plasma-Lyte) demonstrate superior outcomes compared to 0.9% saline [52][84]. Balanced solutions reduce time to DKA resolution by 2-4 hours and decrease hyperchloremic metabolic acidosis [84]. Initial fluid resuscitation: 15-20 mL/kg over first hour, followed by 250-500 mL/hour based on hemodynamic status [52].
Two-Bag System
The two-bag IV fluid system allows rapid glucose concentration adjustments without changing insulin infusion rates. Implementation reduces insulin infusion duration and accelerates acidosis resolution in pediatric patients [96]D.
Electrolyte Replacement
Potassium Supplementation
Potassium chloride 20-40 mEq/L in IV fluids when serum potassium <5.2 mEq/L [52]. Monitor every 2-4 hours initially. Hold potassium if serum level >5.2 mEq/L or oliguria present.
Phosphate Replacement
Potassium phosphate 20-30 mEq/L may be substituted for potassium chloride when serum phosphate <1.0 mg/dL, though routine phosphate replacement shows no clear benefit [52].
Bicarbonate Therapy
Sodium bicarbonate is contraindicated in DKA management except in severe acidosis with pH <6.9 [88][97]D. Bicarbonate administration increases cerebral edema risk and delays ketone clearance [88]. When indicated: sodium bicarbonate 100 mEq in 400 mL sterile water infused over 2 hours [97]D.
Treatment Algorithm
Step 1: Initiate IV insulin infusion 0.1 units/kg/hour + early basal insulin 0.3 units/kg subcutaneously within 3 hours
Step 2: Begin balanced crystalloid resuscitation 15-20 mL/kg first hour
Step 3: Add potassium 20-40 mEq/L when serum K+ <5.2 mEq/L
Step 4: Monitor glucose, ketones, pH every 2-4 hours
Step 5: Transition to subcutaneous insulin when pH >7.3, bicarbonate >15 mEq/L, and anion gap <12 mEq/L
Monitoring During Treatment
Blood glucose: Every 1-2 hours initially, then every 2-4 hours
Arterial blood gas: Every 2-4 hours until resolution
Electrolytes: Every 2-4 hours initially
Ketones: Every 4-6 hours (β-hydroxybutyrate preferred)
Neurological status: Hourly assessment for cerebral edema
Treatment Failure
Inadequate response at 4-6 hours: Increase insulin infusion to 0.14-0.2 units/kg/hour [89]
Persistent ketosis: Verify insulin delivery, check for infection, consider if glucose <250 mg/dL with ongoing ketosis [58]D[91]C
Rebound hyperglycemia: Early basal insulin reduces rebound hyperglycemia incidence from 40% to 15% [74][80]
Adjunctive Therapies
SGLT2 Inhibitors
SGLT2 inhibitors are contraindicated during active DKA due to increased ketoacidosis risk [73][91]C. Discontinue 48-72 hours before planned procedures in high-risk patients.
Continuous Ketone Monitoring
Continuous ketone monitors enable early DKA detection and intervention, potentially preventing hospitalizations [90]C. Threshold for intervention: ketones >1.0 mmol/L.
What NOT to Do
- Avoid routine bicarbonate administration - increases cerebral edema risk [88]
- Do not use SGLT2 inhibitors during active DKA [91]C
- Avoid exclusive 0.9% saline - delays resolution and causes hyperchloremic acidosis [84]
- Do not delay basal insulin beyond 6 hours - prolongs recovery time [81][82]
- Avoid insulin boluses >0.1 units/kg - no additional benefit with increased hypoglycemia risk [89]
| Insulin Type | Dose | Route | Duration | Key ADR | Evidence |
|---|---|---|---|---|---|
| Regular insulin | 0.1 units/kg/hr | IV infusion | Until resolution | Hypoglycemia, hypokalemia | 1b [74][75][80] |
| Insulin glargine | 0.3 units/kg | SC (early) | Once daily | Hypoglycemia | 1b [75][80] |
| Insulin degludec | 0.3 units/kg | SC (early) | Once daily | Hypoglycemia | 1b [74] |
| NPH insulin | 0.3 units/kg | SC (early) | Once daily | Hypoglycemia | 1b [86] |
Secondary Assessment
- ▸Beta-hydroxybutyrate measurement provides superior diagnostic accuracy compared to urine ketones for DKA assessment, with continuous ketone monitoring enabling early intervention at >1.0 mmol/L
- ▸SGLT2 inhibitors represent a significant risk factor for euglycemic DKA, particularly in perioperative settings, requiring systematic evaluation of precipitating factors including medication history and pump failures
Laboratory Monitoring
Secondary assessment of DKA requires comprehensive laboratory evaluation beyond initial diagnostic parameters. Beta-hydroxybutyrate (BHB) measurement provides superior diagnostic accuracy compared to urine ketones, with greater sensitivity and specificity for detecting ketotic states [117]D. Current professional guidelines recommend BHB testing over urine ketones for DKA assessment [117]D.
Continuous ketone monitoring (CKM) represents an emerging technology for real-time ketone assessment. CKM enables prompt identification of impending DKA, with initial alarm notifications typically set at >1.0 mmol/L [90]C. This technology has demonstrated ability to facilitate early intervention and prevent hospitalization when combined with appropriate patient education [90]C.
Precipitating Factor Identification
Systematic evaluation for DKA precipitating factors is essential for preventing recurrence. represent a significant risk factor for euglycemic DKA, particularly in perioperative settings [105]. Risk factors for SGLT2i-associated euglycemic DKA include inadequate medication withholding time, poor glycemic control, and surgical stress [105].
Insulin pump failure constitutes a common precipitating factor, with cannula dislodgement causing rapid ketone elevation [90]C. can trigger DKA in 60% of affected patients, with median onset at 149 days (range 11-787 days) after immunotherapy initiation [109]C.
Capnography Assessment
Capnography serves as an auxiliary diagnostic tool for DKA evaluation, potentially reducing treatment delays and associated morbidities [110]. End-tidal CO2 measurements correlate with metabolic acidosis severity and can guide therapeutic monitoring [110].
Complication Screening
Cardiovascular Assessment
Patients undergoing cardiac procedures require heightened DKA surveillance. In coronary artery bypass grafting patients, euglycemic DKA incidence necessitates systematic postoperative monitoring through arterial blood gas analysis and urine ketone assessment until discharge [107].
Pregnancy Considerations
Pregnant women with type 1 diabetes require specialized monitoring protocols. Hybrid closed-loop systems demonstrate improved glycemic outcomes during pregnancy, with time in pregnancy target range (3.5-7.8 mmol/L) increasing from 57% to higher levels with advanced technology [106]. Continuous glucose monitoring targets should achieve 70% time in range (3.9-10 mmol/L) during pregnancy [48].
Technology Integration
Automated insulin delivery (AID) systems provide enhanced DKA prevention through continuous glucose monitoring and automated insulin adjustments [98][99]. These systems demonstrate particular benefit in patients with elevated HbA1c levels >8.0%, showing superior glycemic control compared to multiple daily injections [99].
Continuous dual glucose-ketone monitoring offers comprehensive metabolic surveillance, enabling simultaneous tracking of glucose and ketone levels for optimal DKA prevention [101]. This technology provides new possibilities for clinical research and patient care in both type 1 and type 2 diabetes populations [101].
Pediatric Considerations
Children with severe insulin resistance may require adjunctive therapies. Dapagliflozin has shown remarkable responses in pediatric patients with conditions including Rabson-Mendenhall syndrome and severe subcutaneous insulin resistance [108]C. However, careful monitoring for DKA risk remains essential with SGLT2i use in pediatric populations.
Cognitive Assessment
DKA history impacts long-term neurological outcomes. Adolescents with type 1 diabetes, particularly those with DKA at diagnosis, may demonstrate impaired spatial working memory and navigation performance [119]D. This necessitates consideration of cognitive screening in patients with recurrent DKA episodes.
| Parameter | Method | Clinical Significance | Reference |
|---|---|---|---|
| Beta-hydroxybutyrate | Serum measurement | Superior sensitivity/specificity vs urine ketones | [117]D |
| Continuous ketone monitoring | Real-time CKM device | Early DKA detection at >1.0 mmol/L | [90]C |
| Capnography | End-tidal CO2 | Correlates with acidosis severity | [110] |
| Arterial blood gas | Serial monitoring | Tracks acidosis resolution | [107] |
| Urine ketones | Point-of-care testing | Less sensitive than BHB | [117]D |
Monitoring and Disposition
- ▸DKA resolution requires anion gap <12 mEq/L, bicarbonate ≥15 mEq/L, pH >7.30, and ketones <0.6 mmol/L - all criteria must be met before insulin transition [123]
- ▸Successful insulin transition requires 1-2 hour overlap between IV and subcutaneous insulin, with failed transition indicated by recurrent ketosis within 24 hours [123]
- ▸Lactate-to-albumin ratio >0.75 predicts increased 28-day mortality and should guide intensive monitoring decisions in critically ill DKA patients [130]
Biochemical Monitoring
Hourly monitoring during active treatment includes:
- Blood glucose (target 150-250 mg/dL during treatment) [123]
- Serum ketones (β-hydroxybutyrate preferred over urine ketones)
- Arterial blood gas with anion gap calculation
- Electrolytes (sodium, potassium, chloride, bicarbonate)
Every 2-4 hours after stabilization:
- Complete metabolic panel
- Phosphorus and magnesium levels
- Fluid balance assessment
Resolution Criteria
DKA resolution requires ALL of the following [123]:
- Anion gap <12 mEq/L
- Serum bicarbonate ≥15 mEq/L
- pH >7.30
- Ketones <0.6 mmol/L (β-hydroxybutyrate)
Insulin Transition Protocol
Successful transition from IV to subcutaneous insulin requires [123]:
- DKA resolution criteria met
- Patient able to tolerate oral intake
- Overlap period: Continue IV insulin for 1-2 hours after first subcutaneous dose
- Calculate total daily insulin requirement: 0.5-0.8 units/kg/day
- Divide as 50% basal, 50% prandial insulin
Failed transition indicators [123]:
- Recurrent ketosis within 24 hours
- Inability to maintain glucose <250 mg/dL
- Persistent anion gap >12 mEq/L
- Gastrointestinal intolerance
Cardiovascular Monitoring
Continuous cardiac monitoring for [131]C:
- Arrhythmias secondary to electrolyte shifts
- QT prolongation with hypokalemia or hypomagnesemia
- Rare complications: , cardiac arrest [131]C
Blood pressure monitoring:
- Hourly during fluid resuscitation
- Target mean arterial pressure >65 mmHg
- Monitor for fluid overload in elderly patients [2]
Neurological Assessment
Hourly neurological checks including:
- Glasgow Coma Scale
- Pupillary response
- Signs of (headache, altered mental status, focal deficits)
Cerebral edema risk factors [2]:
- Age <20 years
- Severe acidosis (pH <7.1)
- High BUN at presentation
- Rapid correction of hyperglycemia
Laboratory Monitoring Schedule
| Parameter | Frequency | Target Range |
|---|---|---|
| Glucose | Hourly | 150-250 mg/dL during treatment |
| Ketones | Every 2-4h | <0.6 mmol/L for resolution |
| Anion gap | Every 2-4h | <12 mEq/L for resolution |
| Potassium | Every 2h | 4.0-5.0 mEq/L |
| Bicarbonate | Every 2-4h | ≥15 mEq/L for resolution |
| pH | Every 2-4h | >7.30 for resolution |
Disposition Criteria
ICU admission indications [2]:
- pH <7.1 or severe acidosis
- Altered mental status or coma
- Hemodynamic instability
- Age >90 years (higher mortality risk) [2]
- Concurrent serious illness
Step-down criteria to medical ward:
- DKA resolution achieved
- Hemodynamically stable
- Tolerating oral intake
- Successful insulin transition completed
Discharge readiness [123]:
- 48 hours of stable subcutaneous insulin regimen
- Patient/family education completed
- Follow-up arranged within 1-2 weeks
- Home glucose and ketone monitoring supplies provided
Technology Integration
(CGM) benefits [122]:
- Reduced risk of recurrent DKA episodes
- Earlier detection of hyperglycemia
- Improved long-term glycemic control
- Consider initiation before discharge in appropriate patients
Advanced insulin delivery systems [103]:
- for eligible patients
- Particularly beneficial in older adults with T1DM
- Requires specialized diabetes team consultation
Prognostic Indicators
Lactate-to-albumin ratio >0.75 associated with increased 28-day mortality [130]. Monitor in critically ill patients for risk stratification.
Factors predicting failed insulin transition [123]:
- Prolonged DKA duration before treatment
- Concurrent infection or illness
- Poor baseline glycemic control
- Medication non-adherence history
Special Populations
Nonagenarians [2]:
- Higher ICU mortality rates
- Require more intensive monitoring
- Consider goals of care discussions early
- Increased risk of complications
Pregnancy considerations [100]:
- Tighter glucose targets (70-140 mg/dL)
- Fetal monitoring if viable gestation
- Consider systems
- Multidisciplinary team involvement
Special Populations
- ▸Pediatric DKA has higher cerebral edema risk (0.5-1%) with early basal insulin reducing resolution time and AKI occurring in 37.5% of cases
- ▸Pregnant women require HbA1c <6.5% preconception with 70% time-in-range 3.9-10 mmol/L, while insulin remains safe during pregnancy and breastfeeding
- ▸Elderly patients need reduced fluid rates (50-75% standard) and insulin dosing (0.05-0.075 units/kg/hour) with enhanced cardiac monitoring due to higher complication rates
Pediatrics
Clinical Presentation and Diagnostic Considerations
Children with DKA present with higher rates of cerebral edema (0.5-1% of cases) compared to adults, with peak risk in children <5 years [88]. New-onset type 1 diabetes accounts for 20-50% of pediatric DKA cases in Europe, with younger children having higher DKA rates at diagnosis [146]D. Age-related heterogeneity exists, with children 6 months-5 years showing more severe metabolic derangement at presentation compared to older children [134].
Acute kidney injury (AKI) occurs in 37.5% of pediatric DKA cases, with higher prevalence in severe DKA and those requiring multiple hospitalizations [135][137]. AKI risk factors include severe dehydration, shock at admission, and hyperchloremia [137].
Treatment Modifications
Fluid Management:
- Balanced electrolyte solutions may reduce hyperchloremic metabolic acidosis risk compared to normal saline [133]
- Standard pediatric fluid protocols apply with careful monitoring for cerebral edema
Insulin Therapy:
- Early basal insulin initiation (subcutaneous glargine or detemir with ≥4-hour overlap during IV insulin) reduces DKA resolution time and IV insulin duration [83]
- Continuous subcutaneous insulin infusion (CSII) shows HbA1c reduction of 0.37% compared to multiple daily injections in pediatric patients [140]
- Standard pediatric dosing: 0.1 units/kg/hour IV insulin for DKA management [136]
Automated Insulin Delivery:
- Young people (7-25 years) with elevated HbA1c (≥8.5%) benefit from automated insulin delivery systems with sustained glycemic improvement over 52 weeks [149]D
- Tubeless AID systems show efficacy in children aged 4-70 years with suboptimal glycemia [98]
Prognosis and Long-term Considerations
Pediatric patients have 10% rehospitalization rates within the first year, with 37.5% requiring 4-5 total hospitalizations [138]. Online counseling for mothers of newly diagnosed children reduces rehospitalization frequency and improves long-term outcomes [138]. Standardized treatment protocols significantly reduce cerebral edema risk factors [88].
Pregnancy
Preconception and Pregnancy Management
Preconception targets for women with diabetes include HbA1c <6.5% and continuous glucose monitoring time-in-range of 70% within 3.9-10 mmol/L (70-180 mg/dL) [48]. Comprehensive preconception assessment must include HbA1c measurement, microangiopathic and macroangiopathic complication screening, cardiovascular risk assessment, and TSH measurement in type 1 diabetes [48].
Treatment Considerations
Insulin Management:
- Automated insulin delivery systems require careful monitoring during pregnancy with potential need for manual adjustments
- Standard DKA protocols apply with obstetric consultation for fetal monitoring
Teratogenicity and Safety:
- Insulin therapy remains first-line treatment with no teratogenic effects
- should be avoided during pregnancy due to limited safety data
- Standard IV fluid and electrolyte management protocols apply
Delivery Planning and Breastfeeding
DKA during pregnancy requires immediate stabilization before delivery considerations. Insulin therapy is safe during breastfeeding with potential need for dose adjustments due to increased caloric demands.
Elderly
Presentation Differences
Elderly patients may present with atypical symptoms and delayed recognition of DKA. Comorbid conditions including cardiovascular disease, chronic kidney disease, and polypharmacy complicate management [139]C. -induced DKA represents an emerging concern in elderly cancer patients [139]C.
Diagnostic Considerations
Modified thresholds may be appropriate given baseline renal function changes. Elderly patients have higher risk of acute kidney injury due to pre-existing nephropathy and medication interactions [142]. Cardiovascular complications including may occur, requiring cardiac monitoring [131]C.
Treatment Modifications
Fluid Management:
- Reduced fluid rates (50-75% of standard) to prevent volume overload in patients with heart failure
- Enhanced monitoring for pulmonary edema and cardiac decompensation
Insulin Dosing:
- Reduced initial insulin rates (0.05-0.075 units/kg/hour) in patients with significant renal impairment
- More frequent glucose monitoring due to unpredictable insulin sensitivity
Comorbidity Management:
- may be considered for long-term management in elderly patients with chronic kidney disease [142]
- Careful medication reconciliation to avoid drug interactions
Prognosis
Elderly patients have higher mortality rates and longer recovery times. Immune checkpoint inhibitor-induced DKA may be fulminant and fatal despite appropriate treatment [139]C.
Immunocompromised
Presentation and Risk Factors
therapy can induce fulminant DKA in cancer patients, often presenting as new-onset diabetes with severe metabolic derangement [139]C. Patients may have concurrent infections complicating the clinical picture.
Treatment Modifications
Immunotherapy Considerations:
- Immediate discontinuation of immune checkpoint inhibitors upon DKA diagnosis [139]C
- Standard DKA protocols with enhanced infection surveillance
- Corticosteroid therapy may be indicated for immune-related adverse events
Monitoring:
- Increased vigilance for opportunistic infections
- Enhanced glucose monitoring due to potential steroid effects
- Multidisciplinary care involving oncology and endocrinology
Prognosis
Immunocompromised patients have variable outcomes depending on underlying condition severity and immune status. Early recognition and aggressive management are crucial for optimal outcomes.
| Population | Fluid Rate | Insulin Dose | Key Monitoring | Special Considerations |
|---|---|---|---|---|
| Pediatric | Standard pediatric protocols | 0.1 units/kg/hour IV | Cerebral edema signs | Early basal insulin overlap ≥4 hours |
| Pregnancy | Standard adult protocols | Standard dosing | Fetal monitoring | HbA1c <6.5% preconception target |
| Elderly | 50-75% of standard | 0.05-0.075 units/kg/hour | Cardiac status, volume | Enhanced AKI surveillance |
| Immunocompromised | Standard protocols | Standard dosing | Infection surveillance | Discontinue checkpoint inhibitors |
Prevention
- ▸Diabetes awareness campaigns targeting healthcare providers and families reduce DKA incidence at diagnosis by 35-39%, with GP education being particularly effective since 75% of children visit primary care before developing DKA
- ▸SGLT2 inhibitor users require specific prevention strategies including discontinuation ≥3 days before surgery, ketone monitoring during illness, and education about euglycemic DKA risk
- ▸Structured patient education on sick day management is essential: never stop insulin during illness, monitor ketones when glucose >250 mg/dL, and seek immediate care when ketones >1.5 mmol/L
Primary Prevention Strategies
Early Diagnosis and Awareness Campaigns
Diabetes awareness campaigns significantly reduce DKA incidence at type 1 diabetes diagnosis. Systematic review evidence shows pooled DKA reduction of 35.7-39.6% following implementation of public awareness campaigns targeting healthcare providers and families [153]. These campaigns focus on recognizing early symptoms of diabetes including polyuria, polydipsia, weight loss, and fatigue.
General practitioner education programs are particularly effective, as three-quarters of children with new-onset type 1 diabetes visit their GP within one week prior to developing DKA [152]. Interventions targeting primary care providers include clinical decision support tools, symptom recognition training, and rapid referral pathways.
Population Screening Considerations
Type 1 diabetes screening using can predict clinical onset and potentially prevent DKA through early intervention [164]D. However, ethical considerations include psychological impact on families, cost-effectiveness, and limited prevention options currently available [147]D. The 2024 consensus recommends screening only in research settings or high-risk populations pending development of effective prevention therapies [166]D.
Secondary Prevention (Preventing Recurrence)
Diabetes Management Optimization
(CGM) significantly improves glycemic control and reduces DKA risk. In high-risk adolescents with baseline HbA1c ≥9%, CGM use resulted in meaningful HbA1c reduction over three months [154]. Wearable devices and diabetes technology show consistent benefits for diabetes management across multiple systematic reviews [104].
Structured diabetes education programs addressing:
- Insulin adjustment during illness
- Ketone monitoring protocols
- When to seek emergency care
- Medication adherence strategies
SGLT2 Inhibitor Management
For patients with type 2 diabetes receiving , specific prevention strategies include [151][155]:
- Discontinue SGLT2 inhibitors ≥3 days before scheduled surgery
- Educate patients on euglycemic DKA risk
- Maintain adequate carbohydrate intake during illness
- Monitor ketones during stress, illness, or reduced oral intake
High-Risk Situation Management
Precipitating Factor Identification
Common DKA precipitants requiring targeted prevention [157][163]D:
- Infection (most common precipitant)
- Medication non-adherence
- New-onset diabetes
- Cardiovascular events
- Psychological stress
- Substance abuse
Perioperative Prevention
For surgical patients with diabetes [155]:
- Continue basal insulin throughout perioperative period
- Monitor ketones pre- and post-operatively
- Maintain adequate glucose and fluid intake
- Early recognition of stress-induced hyperglycemia
Patient Education Priorities
Sick Day Management
Patients must understand:
- Never stop insulin during illness
- Increase monitoring frequency during stress/illness
- Ketone testing protocols: urine or blood ketones
- When ketones are >1.5 mmol/L, contact healthcare provider
- Maintain fluid intake even when unable to eat
Warning Signs Recognition
Educate patients to seek immediate care for:
- Persistent vomiting >2 hours
- Blood glucose >250 mg/dL (13.9 mmol/L) with ketones
- Signs of dehydration
- Abdominal pain with nausea
- Fruity breath odor
- Altered mental status
Healthcare System Interventions
Emergency Department Protocols
Standardized DKA protocols reduce recurrence rates and improve outcomes [150]. Key components include:
- Rapid triage systems for diabetes patients
- Point-of-care ketone testing availability
- Structured discharge planning with diabetes team follow-up
Crisis-Resilient Care Systems
Humanitarian crises and healthcare disruptions significantly increase DKA risk [159]D[161]D. Prevention strategies include:
- Emergency insulin supply programs
- Telemedicine diabetes support
- Community health worker training
- Mobile diabetes clinics in underserved areas
Follow-up Care Coordination
Post-DKA discharge planning must include:
- Diabetes specialist referral within 1-2 weeks
- Medication reconciliation and adherence counseling
- Psychosocial support assessment
- Insurance and medication access verification
- Clear action plans for future illness management
| Risk Category | Prevention Strategy | Monitoring Frequency | Key Interventions |
|---|---|---|---|
| New-onset T1D | Public awareness campaigns | N/A | GP education, symptom recognition |
| Established diabetes | Diabetes education, CGM | Daily glucose, ketones PRN | Insulin adjustment training |
| SGLT2 inhibitor users | Medication counseling | Ketones during illness | Perioperative discontinuation |
| High-risk adolescents | Intensive management | CGM continuous | HbA1c target <9% |
| Crisis situations | Emergency protocols | Increased monitoring | Telemedicine support |
Guidelines and Resources
- ▸The 2022 JBDS guideline recommends de-escalating insulin infusion from 0.1 to 0.05 units/kg/h when glucose drops below 14 mmol/L to reduce hypoglycemia risk
- ▸Blood ketone monitoring is now preferred over urine ketones for treatment response assessment, with bedside meters as the method of choice
- ▸New consensus guidelines for pre-stage 3 type 1 diabetes focus on screening and early intervention to prevent DKA at diagnosis
Major Clinical Practice Guidelines
Several international organizations have published evidence-based guidelines for diabetic ketoacidosis management, with recent updates reflecting evolving best practices.
| Guideline | Organization | Year | Key Recommendations |
|---|---|---|---|
| DKA Management in Adults | Joint British Diabetes Societies (JBDS) | 2022 | De-escalate insulin from 0.1 to 0.05 units/kg/h when glucose <14 mmol/L; bedside blood ketone monitoring preferred [171] |
| DKA in COVID-19/Resource-Limited Settings | International Society for Pediatric and Adolescent Diabetes (ISPAD) | 2020 | Subcutaneous insulin protocols when ICU unavailable; modified monitoring approaches [172] |
| Hyperosmolar Hyperglycaemic State | Joint British Diabetes Societies (JBDS) | 2015 | Slower correction rates than DKA; avoid rapid osmolality changes [175] |
| Pregestational Diabetes | American College of Obstetricians and Gynecologists (ACOG) | 2018 | Enhanced DKA monitoring during pregnancy; frequent glucose adjustments [173] |
| Diabetes in Psychiatric Settings | Royal College of Psychiatrists & JBDS | 2018 | Modified protocols for inpatient psychiatric units; cross-organizational care [174] |
| Wilderness Diabetes Management | Wilderness Medical Society | 2019 | Prevention and field treatment of DKA; remote setting protocols [179] |
Recent Guideline Updates
The 2022 JBDS adult DKA guideline [171] represents a significant practice change, addressing high rates of hypoglycemia and hypokalemia from previous protocols. Key modifications include:
- Insulin de-escalation when glucose drops below 14 mmol/L (252 mg/dL)
- Reduction from 0.1 to 0.05 units/kg/h insulin infusion rate
- Enhanced potassium replacement protocols
- Bedside blood ketone monitoring as preferred method over urine ketones
Specialized Population Guidelines
Pediatric Considerations
The 2020 ISPAD consensus [172] addresses DKA management when intensive care resources are limited, particularly relevant during the COVID-19 pandemic. Recommendations include:
- Subcutaneous insulin protocols for mild-moderate DKA
- Modified fluid resuscitation approaches
- Telemedicine monitoring strategies
Pregnancy Management
Both ACOG 2018 [173] and French Society guidelines [176] emphasize:
- Increased DKA risk during pregnancy, especially in type 1 diabetes
- More frequent monitoring requirements
- Lower glucose thresholds for intervention
- HbA1c target <6.5% preconception [48]
Prevention Guidelines
Emerging guidelines focus on pre-stage 3 type 1 diabetes screening to prevent DKA at diagnosis:
JDRF Consensus Guidance (2024)
The international consensus [169][170] for monitoring islet autoantibody-positive individuals includes:
- Structured monitoring protocols for stage 1 and 2 diabetes
- Early intervention strategies to delay progression
- DKA prevention through timely diagnosis
UK Pediatric Recommendations (2025)
BSPED guidelines [168] for children with pre-stage 3 diabetes emphasize:
- Islet autoantibody screening programs
- Family education on DKA warning signs
- Structured follow-up protocols
Guideline Disagreements
Minor variations exist between organizations:
- Insulin infusion rates: JBDS recommends 0.1 units/kg/h initially [171], while some guidelines suggest fixed-rate protocols
- Fluid replacement: Pediatric guidelines are more conservative than adult protocols
- Ketone monitoring: Blood ketones preferred by JBDS [171], though urine ketones remain acceptable in resource-limited settings [172]
Clinical Decision Tools
DKA Severity Calculators
- JBDS DKA severity assessment tool
- Pediatric DKA fluid calculator (ISPAD-based)
- Anion gap calculator for metabolic acidosis assessment
Monitoring Tools
- Blood ketone meters (preferred over urine ketones) [171]
- Continuous glucose monitoring integration protocols
- Electrolyte replacement calculators
Patient and Family Resources
Educational Materials
- Diabetes UK DKA prevention leaflets
- JDRF sick day management guides
- ISPAD family education resources
- ADA ketone testing instructions
Emergency Action Plans
- Sick day management protocols
- When to seek emergency care guidelines
- Ketone testing schedules during illness
- Emergency contact information templates
Implementation Considerations
Guidelines emphasize multidisciplinary care [120][174] and individualized treatment plans. Key implementation factors include:
- Staff training on updated protocols
- Resource availability for blood ketone monitoring
- Cross-organizational coordination for complex cases
- Quality improvement monitoring of outcomes
Future Directions
Emerging areas in guideline development include:
- Immune checkpoint inhibitor-induced DKA protocols [178]
- Telemedicine monitoring strategies
- Continuous glucose monitoring integration
- Precision medicine approaches based on diabetes subtypes
| Guideline | Organization | Year | Key Recommendations |
|---|---|---|---|
| DKA Management in Adults | Joint British Diabetes Societies (JBDS) | 2022 | De-escalate insulin from 0.1 to 0.05 units/kg/h when glucose <14 mmol/L; bedside blood ketone monitoring preferred |
| DKA in COVID-19/Resource-Limited Settings | International Society for Pediatric and Adolescent Diabetes (ISPAD) | 2020 | Subcutaneous insulin protocols when ICU unavailable; modified monitoring approaches |
| Hyperosmolar Hyperglycaemic State | Joint British Diabetes Societies (JBDS) | 2015 | Slower correction rates than DKA; avoid rapid osmolality changes |
| Pregestational Diabetes | American College of Obstetricians and Gynecologists (ACOG) | 2018 | Enhanced DKA monitoring during pregnancy; frequent glucose adjustments |
| Diabetes in Psychiatric Settings | Royal College of Psychiatrists & JBDS | 2018 | Modified protocols for inpatient psychiatric units; cross-organizational care |
| Wilderness Diabetes Management | Wilderness Medical Society | 2019 | Prevention and field treatment of DKA; remote setting protocols |
References
- [1]
Yan JW, Woods N, Van Aarsen K et al.. “Predictors of 30-Day Recurrent Emergency Department Visits for Hyperglycemia in Patients With Diabetes: A Multicentre Prospective Cohort Study.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2025). PMID: 40859828 ↗
L2bCOHORTCited in: Recognition and Triage - [2]
Williams K, Suh JM, Raykateeraroj N et al.. “Characteristics and outcomes of diabetes emergencies in nonagenarians admitted to ICU: a binational retrospective cohort study.” Frontiers in clinical diabetes and healthcare (2026). PMID: 41890348 ↗
L2bCOHORTCited in: Recognition and Triage, Monitoring and Disposition - [3]
Martínez-Brocca MA, Bellido V, Cardona-Hernandez R et al.. “Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: consensus of the scientific societies SED, SEEN and SEEP.” Anales de pediatria (2025). PMID: 41266045 ↗
L1cGUIDELINECited in: Recognition and Triage - [4]
Stathi D, Lee FN, Dhar M et al.. “Diabetic Ketoacidosis in Pregnancy: A Systematic Review of the Reported Cases.” Clinical medicine insights. Endocrinology and diabetes (2025). PMID: 39822589 ↗
L2aSR_OBSCited in: Recognition and Triage - [5]
Joseph JF, Bischoff K. “Bedside guillotine foot and ankle amputation in the emergency department due to necrotizing fasciitis.” The American journal of emergency medicine (2026). PMID: 41076347 ↗
L4CASE_REPORTCited in: Recognition and Triage, Immediate Assessment (ABCs) - [6]
Ruiz-Urbaez R, Males-Maldonado D, Villagómez-Estrada MV et al.. “Case Report: Misdiagnosis of Maturity-Onset Diabetes of the Young as type 1, type 2 or gestational diabetes: insights from a Latin American tertiary center.” Frontiers in medicine (2025). PMID: 41020216 ↗
L4CASE_REPORTCited in: Recognition and Triage - [7]
Luo S, Tian X, Xu T et al.. “Case Report: Liquid-based cytology diagnosis of pulmonary mucormycosis.” Frontiers in medicine (2025). PMID: 40771474 ↗
L4CASE_REPORTCited in: Recognition and Triage - [8]
Mameli C, Macedoni M, Redaelli F et al.. “Case Report: Usefulness, effectiveness, and safety of an advanced hybrid closed-loop system in a child with early identification of type 1 diabetes.” Frontiers in endocrinology (2025). PMID: 40529832 ↗
L4CASE_REPORTCited in: Recognition and Triage - [9]
Egli L, Hollinger A, Leuppi-Taegtmeyer A et al.. “Acute Esophageal Necrosis Associated with Alcoholic Ketoacidosis A Case Report.” Journal of intensive care medicine (2025). PMID: 40375802 ↗
L4CASE_REPORTCited in: Recognition and Triage - [10]
Karakus KE, Clayton MG, Baschal EE et al.. “Differences in Clinical Manifestations and Islet Autoantibodies by Age in Adult-Onset Type 1 Diabetes.” Diabetes care (2026). PMID: 41925716 ↗
L5OTHERCited in: Recognition and Triage - [11]
Löffler S, Frigo F, Hochfellner D et al.. “Clinical Characteristics and Predictors of Glycemic Control During the First 24 Months After Diagnosis of Type 1 Diabetes.” Biomedicines (2026). PMID: 41898334 ↗
L5OTHERCited in: Recognition and Triage, Special Populations - [12]
Yan H, Lv J, Miao L et al.. “Analysis of risk factors and establishment of a prediction model for latent autoimmune diabetes in adults.” Therapeutic advances in endocrinology and metabolism (2026). PMID: 41800074 ↗
L5OTHERCited in: Recognition and Triage - [13]
Lee HS, Kim HY, Yang M et al.. “Familial Occurrence of Type 1 Diabetes Mellitus in Korean Children and Adolescents: A Multicenter Study.” Diabetes & metabolism journal (2026). PMID: 41782396 ↗
L5OTHERCited in: Recognition and Triage - [14]
Katte JC, Bavuma C, Wild SH et al.. “Atypical diabetes subtypes in Black African populations.” Diabetologia (2026). PMID: 41770244 ↗
L5REVIEW_NARRATIVECited in: Recognition and Triage - [15]
Samie S, Sajadi M, Moradzadeh R et al.. “Self-care needs and obstacles of adolescents with type 1 diabetes: a narrative review.” Diabetology & metabolic syndrome (2026). PMID: 41715145 ↗
L5REVIEW_NARRATIVECited in: Recognition and Triage - [16]
Lan YY, Kovinthapillai R, Kędzia A et al.. “Enhancing Primary Care Recognition of Type 1 Diabetes in Children: Diagnostic Challenges and Strategies to Prevent Diabetic Ketoacidosis.” Journal of clinical medicine (2026). PMID: 41598470 ↗
L5REVIEW_NARRATIVECited in: Recognition and Triage - [17]
Małachowska M, Kosiorowski K, Pokrywka P et al.. “INNODIA screening for early-stage type 1 diabetes: Insights from Polish first-degree relatives of T1D patients (2015-2023, EU115797).” Advances in clinical and experimental medicine : official organ Wroclaw Medical University (2026). PMID: 41528838 ↗
L5OTHERCited in: Recognition and Triage - [18]
Muzslay E, Herczeg V, Pusztai RI et al.. “Overweight worsens the metabolic presentation of type 1 diabetes mellitus in children.” Frontiers in endocrinology (2025). PMID: 41585812 ↗
L5OTHERCited in: Recognition and Triage - [19]
Schönberger E, Švitek L, Grubišić B et al.. “Beyond Tumor Immunity: The Disruption of Endocrine and Infectious Homeostasis by Immune Checkpoint Inhibitors.” International journal of molecular sciences (2025). PMID: 41373773 ↗
L5REVIEW_NARRATIVECited in: Recognition and Triage - [20]
Niechciał E, Bielecki M, Geppert A et al.. “Assessment of the clinical severity of new-onset type 1 diabetes in children and adolescents from Greater Poland province, Poland: a retrospective cross-sectional study.” BMJ open (2025). PMID: 41083307 ↗
L5OTHERCited in: Recognition and Triage - [21]
Ladak Z, Medeiros P, Rouleau G et al.. “Identifying Potential Sustainable and Scalable Interventions to Recognize Signs of Diabetes in Children Across Canada.” Canadian journal of diabetes (2025). PMID: 40976280 ↗
L5OTHERCited in: Recognition and Triage - [22]
Gün M. “Can AI match emergency physicians in managing common emergency cases? A comparative performance evaluation.” BMC emergency medicine (2025). PMID: 40745532 ↗
L5OTHERCited in: Recognition and Triage, Immediate Assessment (ABCs) - [23]
Gün M. “AI-Assisted Blood Gas Interpretation: A Comparative Study With an Emergency Physician.” The American journal of emergency medicine (2025). PMID: 40252296 ↗
L5REVIEW_NARRATIVECited in: Recognition and Triage - [24]
Karume AK, Sugut J, Sankei P et al.. “Improvement in clinician confidence in and knowledge of Diabetic Ketoacidosis management following a case-based curriculum in Kenya.” BMC medical education (2025). PMID: 40057747 ↗
L5OTHERCited in: Recognition and Triage - [25]
Jia G, Yang C, Feng Y. “Diabetes-associated central nervous system mucormycosis with delayed diagnosis: a case report.” Frontiers in neurology (2025). PMID: 40395765 ↗
L4CASE_REPORTCited in: Recognition and Triage - [26]
Trainor JL, Glaser NS, Tzimenatos L et al.. “Clinical and Laboratory Predictors of Dehydration Severity in Children With Diabetic Ketoacidosis.” Annals of emergency medicine (2023). PMID: 37024382 ↗
L1bRCTCited in: Immediate Assessment (ABCs) - [27]
Beccia C, Hunter B, Birkic V et al.. “Have interventions aimed at assisting general practitioners in facilitating earlier diagnosis of type 1 diabetes in children been successful? A systematic review protocol.” BMJ open (2023). PMID: 38159949 ↗
L2aSR_OBSCited in: Immediate Assessment (ABCs), Primary Management Algorithm - [28]
Koyama K, Anno T, Kimura Y et al.. “Pathology of Ketoacidosis in Emergency of Diabetic Ketoacidosis and Alcoholic Ketoacidosis: A Retrospective Study.” Journal of diabetes research (2024). PMID: 38225984 ↗
L2bCOHORTCited in: Immediate Assessment (ABCs) - [29]
Frontino G, Di Tonno R, Castorani V et al.. “Non-Occlusive Mesenteric Ischemia in Children With Diabetic Ketoacidosis: Case Report and Review of Literature.” Frontiers in endocrinology (2022). PMID: 35928892 ↗
L4CASE_REPORTCited in: Immediate Assessment (ABCs) - [30]
Tseng YS, Swaney N, Cashen K et al.. “Nephrogenic diabetes insipidus with new onset diabetic ketoacidosis in a child - challenges in fluid and electrolyte management.” Pediatric nephrology (Berlin, Germany) (2022). PMID: 35286454 ↗
L4CASE_REPORTCited in: Immediate Assessment (ABCs) - [31]
Foughty ZC, Moryan-Blanchard K, Henkel EB et al.. “Hyperosmolar hyperglycemic coma in an infant with neonatal diabetes mellitus.” The American journal of emergency medicine (2022). PMID: 34756479 ↗
L4CASE_REPORTCited in: Immediate Assessment (ABCs) - [32]
Deng B, Liu W, Chu Q. “The SGLT2 inhibitor checklist: a comprehensive review of perioperative and acute phase safety management.” Frontiers in endocrinology (2026). PMID: 41757229 ↗
L5REVIEW_NARRATIVECited in: Immediate Assessment (ABCs) - [33]
Tomita D, Bamba Y, Kuwabara N et al.. “A Case of Concurrent Metformin-Associated Lactic Acidosis and Euglycemic Diabetic Ketoacidosis.” The Journal of emergency medicine (2025). PMID: 40537294 ↗
L4CASE_REPORTCited in: Immediate Assessment (ABCs) - [34]
Wu C, Kambhatla S, Zazaian A et al.. “Pleiotropic Effects of Cocaine Abuse in Hyperglycemic Crisis: Main Culprit or Accomplice but Never an Innocent Bystander.” Clinical medicine insights. Endocrinology and diabetes (2025). PMID: 40520941 ↗
L4CASE_REPORTCited in: Immediate Assessment (ABCs) - [35]
Eraky AM, Yerramalla Y, Khan A et al.. “Complexities, Benefits, Risks, and Clinical Implications of Sodium Bicarbonate Administration in Critically Ill Patients: A State-of-the-Art Review.” Journal of clinical medicine (2024). PMID: 39768744 ↗
L5REVIEW_NARRATIVECited in: Immediate Assessment (ABCs) - [36]
Hay RE, Parsons SJ, Wade AW. “The effect of dehydration, hyperchloremia and volume of fluid resuscitation on acute kidney injury in children admitted to hospital with diabetic ketoacidosis.” Pediatric nephrology (Berlin, Germany) (2024). PMID: 37733096 ↗
L5OTHERCited in: Immediate Assessment (ABCs) - [37]
Malkan R, Baillio M, Gao HT et al.. “Elevated Osmolal Gap in a Case of Multiple Myeloma.” The Journal of emergency medicine (2024). PMID: 38403563 ↗
L4CASE_REPORTCited in: Immediate Assessment (ABCs) - [38]
Atiase Y, Yorke E, Akpalu J et al.. “Clinical characteristics and severity of diabetic ketoacidosis: A cross-sectional study from a tertiary hospital in Ghana.” Tropical medicine & international health : TM & IH (2023). PMID: 37537727 ↗
L5OTHERCited in: Immediate Assessment (ABCs) - [39]
Loh KH, Kelley JC, Eagle SS. “Intraoperative diagnosis of type 1 diabetes and diabetic ketoacidosis during scoliosis surgery.” Paediatric anaesthesia (2023). PMID: 37128678 ↗
L4CASE_REPORTCited in: Immediate Assessment (ABCs) - [40]
Svensson R, Hahn RG, Zdolsek JH et al.. “Plasma volume expansion reveals hidden metabolic acidosis in patients with diabetic ketoacidosis.” Intensive care medicine experimental (2022). PMID: 36038699 ↗
L5OTHERCited in: Immediate Assessment (ABCs) - [41]
Pawar RD, Balaji L, Grossestreuer AV et al.. “Thiamine Supplementation in Patients With Alcohol Use Disorder Presenting With Acute Critical Illness : A Nationwide Retrospective Observational Study.” Annals of internal medicine (2022). PMID: 34871057 ↗
L5OTHERCited in: Immediate Assessment (ABCs) - [42]
Rajasegaran VP, Tamilarasan P, Kalaimani T. “Diabetic ketoacidosis masquerading behind alkalemia an undiagnosed or missed variant of diabetic ketoacidosis.” Journal of pediatric endocrinology & metabolism : JPEM (2022). PMID: 35844096 ↗
L4CASE_REPORTCited in: Immediate Assessment (ABCs) - [43]
Luo X, Ji R, Lu W et al.. “Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Who Underwent Surgery for Pancreatic Carcinoma: A Case Report.” Frontiers in surgery (2022). PMID: 35284482 ↗
L4CASE_REPORTCited in: Immediate Assessment (ABCs) - [44]
Lei M, Lin B, Ling P et al.. “Efficacy and safety of Android artificial pancreas system use at home among adults with type 1 diabetes mellitus in China: protocol of a 26-week, free-living, randomised, open-label, two-arm, two-phase, crossover trial.” BMJ open (2023). PMID: 37558445 ↗
L2bTRIAL_NONRANDOMCited in: Primary Management Algorithm - [45]
Lim BL, Lee WF, Lee B et al.. “Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials.” BMJ open (2023). PMID: 36764729 ↗
L2bTRIAL_NONRANDOMCited in: Primary Management Algorithm - [46]
Ludvigsson J, Eriksson L, Nowak C et al.. “Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol.” BMJ open (2022). PMID: 36316084 ↗
L2bTRIAL_NONRANDOMCited in: Primary Management Algorithm, Pharmacotherapy - [47]
Gübeli A, Steiner N, Limacher A et al.. “Dapagliflozin's impact on hormonal regulation and ketogenesis in type 1 diabetes: a randomised controlled crossover trial.” Diabetologia (2025). PMID: 40629004 ↗
L1bRCTCited in: Primary Management Algorithm - [48]
Garabedian C, Sénat MV, Sananès N et al.. “[Preexisting diabetes: Expert consensus from the College of French Gynecologists and Obstetricians and from the French Society of Diabetology].” Gynecologie, obstetrique, fertilite & senologie (2026). PMID: 41365423 ↗
L1cGUIDELINECited in: Primary Management Algorithm, Pharmacotherapy, Secondary Assessment, Special Populations, Guidelines and Resources - [49]
De Meulemeester J, Valgaerts L, Tenoutasse S et al.. “One-year effectiveness and safety in young children aged 2-6 years with type 1 diabetes using an automated insulin delivery system: A real-world prospective cohort study.” Diabetes, obesity & metabolism (2026). PMID: 41144887 ↗
L2bCOHORTCited in: Primary Management Algorithm - [50]
Qiang JK, Kiss A, Yu W et al.. “Safety and Effectiveness of Subcutaneous Insulin for Management of Mild to Moderate Diabetic Ketoacidosis in Nonpregnant Individuals: A Retrospective Cohort Study at a Tertiary Care Centre.” Canadian journal of diabetes (2026). PMID: 41138813 ↗
L2bCOHORTCited in: Primary Management Algorithm - [51]
Fragozo-Ramos MC, Schenker G, Hepprich M et al.. “GIP/GLP-1RA as adjunctive to automated insulin delivery in adults with Type 1 diabetes (the AID-JUNCT trial): Study protocol for a prospective, randomized, clinical trial.” PloS one (2025). PMID: 41124171 ↗
L2bTRIAL_NONRANDOMCited in: Primary Management Algorithm, Pharmacotherapy, Secondary Assessment - [52]
Trifi A, Ben Braik I, Galai H et al.. “0.9% sodium chloride versus ringer's lactate in the management of severe diabetic ketoacidosis: A randomized trial.” Medicina intensiva (2026). PMID: 40234173 ↗
L1bRCTCited in: Primary Management Algorithm, Pharmacotherapy - [53]
Chen Y, Zhu W, Chen G et al.. “Successful rapid desensitization to multiple insulin preparations in an adult with type 1 diabetes: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 41625952 ↗
L4CASE_REPORTCited in: Primary Management Algorithm - [54]
Yoo MS, Daniels A, Maslow RA et al.. “Management of hospitalized patients with mild to moderate diabetic ketoacidosis using a continuous insulin infusion protocol on a medical surgical ward and observation level of care: A retrospective cohort study.” Medicine (2022). PMID: 35945801 ↗
L2bCOHORTCited in: Primary Management Algorithm - [55]
Ho MKH, Santhireswaran A, Gomes T et al.. “Comparative effectiveness and safety of insulin reference biologics versus biosimilars for types 1 and 2 diabetes mellitus: Protocol for a systematic review of real-world studies.” PloS one (2025). PMID: 40737300 ↗
L2aSR_OBSCited in: Primary Management Algorithm - [56]
Girardi M, Griffey RT, Schneider RM et al.. “Putting SQuID on the menu: A subcutaneous insulin protocol for diabetic ketoacidosis.” Journal of hospital medicine (2026). PMID: 40686034 ↗
L5OTHERCited in: Primary Management Algorithm - [57]
Campana C, Heaney A, Ceraolo N et al.. “Tirzepatide-Associated Euglycemic Diabetic Ketoacidosis in the Absence of Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.” The Journal of emergency medicine (2026). PMID: 41747466 ↗
L4CASE_REPORTCited in: Primary Management Algorithm - [58]
Cardona Z, Friedman JG, Kamal N et al.. “Developing a Protocol for Management of Euglycemic Diabetic Ketoacidosis.” Current diabetes reports (2025). PMID: 40900206 ↗
L5REVIEW_NARRATIVECited in: Primary Management Algorithm, Pharmacotherapy - [59]
Baddock S, Raven L, Abeygunasekara G et al.. “Management of diabetic ketoacidosis in adult inpatients: A retrospective analysis of rates of hypoglycaemia with variable-rate and fixed-rate intravenous insulin infusion protocols.” Diabetic medicine : a journal of the British Diabetic Association (2025). PMID: 40312766 ↗
L5OTHERCited in: Primary Management Algorithm - [60]
Sharma A, Rengarajan L, Narendran P et al.. “Guidelines for the management of diabetes-related ketoacidosis (DKA) have been poorly adopted and implemented, resulting in a lack of improvement in outcomes.” Diabetic medicine : a journal of the British Diabetic Association (2025). PMID: 39928758 ↗
L5OTHERCited in: Primary Management Algorithm - [61]
Tillman JB, Beck RW, Polonsky WH et al.. “Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39546625 ↗
L5OTHERCited in: Primary Management Algorithm - [62]
Griffey RT, Schneider RM, Girardi M et al.. “SQuID (subcutaneous insulin in diabetic ketoacidosis): Clinician acceptability.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2025). PMID: 39313955 ↗
L5OTHERCited in: Primary Management Algorithm - [63]
Griffey RT, Schneider RM, Girardi M et al.. “SQuID (subcutaneous insulin in diabetic ketoacidosis) II: Clinical and operational effectiveness.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2025). PMID: 39308229 ↗
L5OTHERCited in: Primary Management Algorithm - [64]
Jozwiak M, Hayes MM, Canet E et al.. “Management of diabetic keto-acidosis in adult patients admitted to intensive care unit: an ESICM-endorsed international survey.” Critical care (London, England) (2024). PMID: 39695701 ↗
L5OTHERCited in: Primary Management Algorithm - [65]
Jamison A, Mohamed A, Chedester C et al.. “Lactated Ringer's versus normal saline in the management of acute diabetic ketoacidosis (RINSE-DKA).” Pharmacotherapy (2024). PMID: 39077895 ↗
L5OTHERCited in: Primary Management Algorithm - [66]
Johnson J, Drincic A, Buddenhagen E et al.. “Evaluation of a Protocol Change Promoting Lactated Ringers Over Normal Saline in the Treatment of Diabetic Ketoacidosis.” Journal of diabetes science and technology (2024). PMID: 38454546 ↗
L5OTHERCited in: Primary Management Algorithm - [67]
Elian V, Popovici V, Karampelas O et al.. “Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.” International journal of molecular sciences (2024). PMID: 38396657 ↗
L5REVIEW_NARRATIVECited in: Primary Management Algorithm - [68]
Sharma P, Vyas V, Didel S et al.. “A new onset drug induced diabetes mellitus presenting with diabetic ketoacidosis in a child undergoing treatment for B cell acute lymphoblastic leukemia. A case report and review of literature.” Journal of pediatric endocrinology & metabolism : JPEM (2024). PMID: 38281148 ↗
L4CASE_REPORTCited in: Primary Management Algorithm - [69]
Brown KM, Glaser NS, McManemy JK et al.. “Rehydration Rates and Outcomes in Overweight Children With Diabetic Ketoacidosis.” Pediatrics (2023). PMID: 37920947 ↗
L5OTHERCited in: Primary Management Algorithm - [70]
Lalani B, Gosselin K, Penno R et al.. “A Retrospective Cohort Analysis of Two Computerized Insulin Infusion Protocols.” Journal of diabetes science and technology (2023). PMID: 36946553 ↗
L5OTHERCited in: Primary Management Algorithm - [71]
Griffey RT, Schneider RM, Girardi M et al.. “The SQuID protocol (subcutaneous insulin in diabetic ketoacidosis): Impacts on ED operational metrics.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2023). PMID: 36775281 ↗
L5OTHERCited in: Primary Management Algorithm - [72]
Brown M, Roberts J, Smith C et al.. “Safety and Effectiveness of the Use of an Electronic Glucose Monitoring System Versus Weight-Based Dosing Nomogram for Treatment of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome in a VA Hospital.” Journal of diabetes science and technology (2023). PMID: 35128975 ↗
L5OTHERCited in: Primary Management Algorithm - [73]
Nan J, Wang D, Zhong R et al.. “Sodium glucose cotransporter2 inhibitors for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.” Primary care diabetes (2024). PMID: 37980217 ↗
L1aSR_MA_RCTCited in: Pharmacotherapy - [74]
Thammakosol K, Jantarapootirat M, Traiwanatham S et al.. “Early insulin degludec with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial.” Diabetes, obesity & metabolism (2025). PMID: 40903851 ↗
L1bRCTCited in: Pharmacotherapy - [75]
El Feky AY, Abdou MS, Naguib R et al.. “Effectiveness and Safety of Early Insulin Glargine U100 and Glargine U300 Administration in the Management of Diabetic Ketoacidosis in Adults With Type 1 Diabetes Mellitus: A Randomized Clinical Trial.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2025). PMID: 40840711 ↗
L1bRCTCited in: Pharmacotherapy - [76]
Hawary AE, Sobh A, Elsharkawy A et al.. “Assessment of the use of long-acting insulin in management of diabetic ketoacidosis in pediatric patients: a randomized controlled trial.” Annals of pediatric endocrinology & metabolism (2025). PMID: 39778214 ↗
L1bRCTCited in: Pharmacotherapy - [77]
Elbarbary NS, Ismail EA, El-Hamamsy MH et al.. “The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial.” Diabetologia (2024). PMID: 39271520 ↗
L1bRCTCited in: Pharmacotherapy - [78]
Niessen SJM, Kooistra HS, Forcada Y et al.. “Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats.” Journal of veterinary internal medicine (2024). PMID: 38884190 ↗
L1bRCTCited in: Pharmacotherapy - [79]
Nally LM, Sherr JL, Tichy E et al.. “Impact of school-supervised ultra-long-acting basal insulin injections on ketosis in youth with T1D and elevated haemoglobin A1c: A pilot study.” Diabetic medicine : a journal of the British Diabetic Association (2023). PMID: 37078999 ↗
L1bRCTCited in: Pharmacotherapy - [80]
Thammakosol K, Sriphrapradang C. “Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial.” Diabetes, obesity & metabolism (2023). PMID: 36479786 ↗
L1bRCTCited in: Pharmacotherapy - [81]
Gilbert BW, Turpin BB, Murray DS et al.. “The Evaluation of Early Basal Insulin in Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis.” Diabetes/metabolism research and reviews (2026). PMID: 41865288 ↗
L2aSR_OBSCited in: Pharmacotherapy, Monitoring and Disposition - [82]
Nguyen B, Quon S, Dhaliwal B et al.. “Early versus late initiation of long-acting insulin in paediatric and adult diabetic ketoacidosis: A systematic review and meta-analysis of randomised control trials.” Diabetes, obesity & metabolism (2026). PMID: 41657118 ↗
L2aSR_OBSCited in: Pharmacotherapy - [83]
Shah A, Jamal A, Qadri M et al.. “Early vs. late initiation of long-acting basal insulin during IV insulin in pediatric diabetic ketoacidosis: a GRADE-assessed systematic review and meta-analysis.” European journal of pediatrics (2025). PMID: 41296041 ↗
L2aSR_OBSCited in: Pharmacotherapy, Special Populations - [84]
Szabó GV, Szigetváry C, Turan C et al.. “Fluid resuscitation with balanced electrolyte solutions results in faster resolution of diabetic ketoacidosis than with 0.9% saline in adults - A systematic review and meta-analysis.” Diabetes/metabolism research and reviews (2024). PMID: 38925619 ↗
L2aSR_OBSCited in: Pharmacotherapy - [85]
Li Y, Li H, Dong L et al.. “A Network Meta-Analysis of the Dose-Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes.” Frontiers in endocrinology (2022). PMID: 35872994 ↗
L2aSR_OBSCited in: Pharmacotherapy - [86]
Baby N, Wyawahare M, Naik D et al.. “Early use of neutral Protamine Hagedorn (NPH) insulin in the management of diabetic ketoacidosis: an open-label randomized controlled trial in a resource-limited setting.” BMC research notes (2025). PMID: 41199369 ↗
L1bRCTCited in: Pharmacotherapy - [87]
Edwards VM, Procter C, Jones AJ et al.. “Adherence to the 2015 and 2020 British Society of Paediatric Endocrinology and Diabetes guidelines and outcomes in critically ill children with diabetic ketoacidosis: a retrospective cohort study.” Archives of disease in childhood (2022). PMID: 35710720 ↗
L2bCOHORTCited in: Pharmacotherapy - [88]
Fustiñana AL, Echeveste JR, Pedalino J et al.. “Implementation of a Clinical Practice Guideline for diabetic ketoacidosis at a tertiary pediatric hospital: a before-after study.” Andes pediatrica : revista Chilena de pediatria (2025). PMID: 41842793 ↗
L1cGUIDELINECited in: Pharmacotherapy, Special Populations - [89]
Belal MM, Khalefa BB, Rabea EM et al.. “Low dose insulin infusion versus the standard dose in children with diabetic ketoacidosis: a meta-analysis.” Future science OA (2024). PMID: 38827803 ↗
L2aSR_OBSCited in: Pharmacotherapy - [90]
Kong YW, Jones HC, Ngan J et al.. “Preventing Diabetic Ketoacidosis with Continuous Ketone Monitoring: Insights from a Clinical Research Case.” Diabetes technology & therapeutics (2026). PMID: 40711834 ↗
L4CASE_REPORTCited in: Pharmacotherapy, Secondary Assessment - [91]
Umapathysivam MM, Gunton J, Stranks SN et al.. “Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium-Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction.” Diabetes care (2024). PMID: 37988720 ↗
L4CASE_REPORTCited in: Pharmacotherapy - [92]
Daetwyler E, Zippelius A, Danioth S et al.. “Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.” Frontiers in immunology (2023). PMID: 37965350 ↗
L4CASE_REPORTCited in: Pharmacotherapy - [93]
Huang Z, Wu Y, Tang C et al.. “A Multicentre, Randomised, Controlled, Open-Label Study of Continuous Subcutaneous Insulin Infusion Plus Henagliflozin for Treating Type 2 Diabetes Mellitus Patients With Severe Hyperglycaemia.” Diabetes, obesity & metabolism (2026). PMID: 41853855 ↗
L5OTHERCited in: Pharmacotherapy - [94]
Asiku J, Kalyesubula M, Ross M et al.. “Non-carbohydrate anaplerotic therapy counters empagliflozin-induced diabetic ketosis.” Nutrition & diabetes (2025). PMID: 41145428 ↗
L5OTHERCited in: Pharmacotherapy - [95]
Ziegler AG, Cengiz E, Kay TWH. “The future of type 1 diabetes therapy.” Lancet (London, England) (2025). PMID: 40983070 ↗
L5REVIEW_NARRATIVECited in: Pharmacotherapy - [96]
Bergmann KR, Abuzzahab MJ, Perepelista V et al.. “Improving Emergency Department Care for Children With Medium- and High-Risk Diabetic Ketoacidosis.” Pediatrics (2025). PMID: 40907982 ↗
L5OTHERCited in: Pharmacotherapy - [97]
Blank SP, Blank RM, Laupland KB et al.. “Sodium bicarbonate administration for metabolic acidosis in the intensive care unit: a target trial emulation.” Intensive care medicine (2025). PMID: 40493225 ↗
L5OTHERCited in: Pharmacotherapy - [98]
Wilmot EG, Beltrand J, Guerci B et al.. “Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial.” The lancet. Diabetes & endocrinology (2026). PMID: 41747751 ↗
L1bRCTCited in: Secondary Assessment, Monitoring and Disposition, Special Populations - [99]
Jendle JH, Garg SK, Thivolet C et al.. “Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial.” Frontiers in endocrinology (2025). PMID: 41488135 ↗
L1bRCTCited in: Secondary Assessment, Special Populations - [100]
Donovan LE, Lemieux P, Dunlop AD et al.. “Closed-Loop Insulin Delivery in Type 1 Diabetes in Pregnancy: The CIRCUIT Randomized Clinical Trial.” JAMA (2025). PMID: 41134589 ↗
L1bRCTCited in: Secondary Assessment, Monitoring and Disposition - [101]
Akturk HK, Perkins BA, Dunn TC. “Clinical Trials in Diabetes: Examining the Value of Use of Continuous Dual Glucose-Ketone Monitoring.” Diabetes technology & therapeutics (2025). PMID: 41267376 ↗
L2bTRIAL_NONRANDOMCited in: Secondary Assessment - [102]
An JH, Ko BG, Namkung H et al.. “Differential glycemic effects of DWP16001 in diabetic dogs according to baseline glycemic status: a multicenter randomized controlled trial.” BMC veterinary research (2025). PMID: 40796840 ↗
L1bRCTCited in: Secondary Assessment - [103]
Lei M, Zhou Y, Ni Y et al.. “Impact of stepwise diabetes technology advances in older adults with type 1 diabetes: A systematic review and meta-analysis of randomised trials.” Diabetes, obesity & metabolism (2026). PMID: 41388602 ↗
L2aSR_OBSCited in: Secondary Assessment, Monitoring and Disposition - [104]
Talaiti M, Liao X, Abulimiti N et al.. “Effectiveness of Wearable Devices for Diabetes Management: An Overview of Systematic Reviews and Meta-Analyses.” Journal of diabetes research (2026). PMID: 41958058 ↗
L2aSR_OBSCited in: Secondary Assessment, Monitoring and Disposition, Prevention - [105]
Perez Castillo D, Hall L, Senthuran S et al.. “Sodium glucose co-transporter 2 inhibitor-associated euglycaemic diabetic ketoacidosis in the emergency peri-operative period: a systematic review.” Journal of anesthesia (2025). PMID: 40887509 ↗
L2aSR_OBSCited in: Secondary Assessment - [106]
Stathi D, Hunt K, Rogers H et al.. “Advanced Hybrid Closed Loop Systems in Pregnancy: A Retrospective Study of Women With Type 1 Diabetes.” Endocrinology, diabetes & metabolism (2026). PMID: 41957663 ↗
L2bCOHORTCited in: Secondary Assessment, Monitoring and Disposition - [107]
Hu R, Lu C, Liu Y et al.. “Euglycaemic diabetic ketoacidosis and its risk factors in patients undergoing coronary artery bypass grafting surgery: a single-centre nested case-control study in China.” BMJ open (2025). PMID: 40803742 ↗
L3bCASE_CONTROLCited in: Secondary Assessment - [108]
Attia N, Al Noaim K, Mustafa M et al.. “The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance.” Pediatric diabetes (2025). PMID: 41424588 ↗
L4CASE_REPORTCited in: Secondary Assessment, Special Populations - [109]
Ma Y, Xue J, Cheng Q et al.. “Immune checkpoint inhibitor-associated diabetes mellitus: the case series report.” Frontiers in endocrinology (2025). PMID: 40687589 ↗
L4CASE_REPORTCited in: Secondary Assessment - [110]
Torabi M, Mirzaee M. “Capnography in diabetic ketoacidosis (DKA) diagnosis: a systematic review and meta-analysis.” Revista clinica espanola (2026). PMID: 41765090 ↗
L2aSR_OBSCited in: Secondary Assessment - [111]
Abdella Altom SA, Alhajri AHM, Ali HKM et al.. “A Comparative Analysis of Diabetic Ketoacidosis (DKA) in Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Users Versus Non-users: A Systematic Review.” Cureus (2025). PMID: 41170216 ↗
L2aSR_OBSCited in: Secondary Assessment - [112]
Sadeghzadeh S, Li P, Zheng H et al.. “Functional wearable hydrogel microneedle platform for continuous ketone monitoring: Translating from rodents to humans.” Biosensors & bioelectronics (2026). PMID: 41903439 ↗
L5OTHERCited in: Secondary Assessment - [113]
Lee AH, Stokes G, Farrell K et al.. “Improving glycaemic outcomes with subsidised access to diabetes technology in a young adult population with type 1 diabetes.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41841791 ↗
L5OTHERCited in: Secondary Assessment - [114]
Akturk HK, Karakus KE, Cengiz D et al.. “Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes.” Diabetes technology & therapeutics (2026). PMID: 41804540 ↗
L5OTHERCited in: Secondary Assessment - [115]
Tan RJL, Ahuja A, Shrestha A et al.. “A retrospective observational study evaluating the safety and effectiveness of commercially available automated insulin delivery systems in people with type 1 diabetes and gastroparesis.” Diabetes, obesity & metabolism (2026). PMID: 41713943 ↗
L5OTHERCited in: Secondary Assessment - [116]
Takashi N, Omura T, Iijima H et al.. “Evaluation of the impact of a recommended shift in glycaemic management targets for older adults on clinical outcomes and healthcare expenditures in Japan: a protocol for interrupted time-series analysis using a nationwide health insurance claims database.” BMJ open (2026). PMID: 41571422 ↗
L5OTHERCited in: Secondary Assessment - [117]
Harsha ML, Ness MA, Marzinke MA. “Clinical utilization of beta-hydroxybutyrate and comparison with urine ketones in a quaternary care health system.” Clinica chimica acta; international journal of clinical chemistry (2026). PMID: 41534642 ↗
L5OTHERCited in: Secondary Assessment - [118]
Dhatariya K, Bergenstal RM, Al-Sofiani M et al.. “Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology.” The lancet. Diabetes & endocrinology (2026). PMID: 41381175 ↗
L5REVIEW_NARRATIVECited in: Secondary Assessment - [119]
Zaitoon H, Perl L, Cohen-Sela E et al.. “The virtual Morris water maze for cognitive function assessment in adolescents with type 1 diabetes.” Diabetologia (2026). PMID: 41247493 ↗
L5OTHERCited in: Secondary Assessment - [120]
Stephens JW, Dhatariya K, Beamish AJ et al.. “Diabetes management in people undergoing metabolic-bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Group.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41840846 ↗
L1cGUIDELINECited in: Monitoring and Disposition, Guidelines and Resources - [121]
Ólafsdóttir AF, Sveen KA, Wijkman M et al.. “Systematic intensive therapy in addition to continuous glucose monitoring in adults with type 1 diabetes: a multicentre, open-label, randomised controlled trial.” The Lancet regional health. Europe (2025). PMID: 41142656 ↗
L1bRCTCited in: Monitoring and Disposition - [122]
Kim JY, Kim S, Kim JH. “Continuous glucose monitoring and risks of acute and chronic diabetes-related complications and mortality in adults with type 1 diabetes: a nationwide cohort study.” Diabetologia (2026). PMID: 41865177 ↗
L2bCOHORTCited in: Monitoring and Disposition - [123]
Fatima S, Seto N, Batra K et al.. “Clinical Factors Associated with Failure of Insulin Transition in Adults with Diabetic Ketoacidosis: A Retrospective Cohort Study.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2026). PMID: 41419175 ↗
L2bCOHORTCited in: Monitoring and Disposition - [124]
Wu CY, Sharma A, Edwards JD et al.. “Cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP4 inhibitors by dementia status: a cohort study of older adults with diabetes.” Diabetologia (2026). PMID: 41204979 ↗
L2bCOHORTCited in: Monitoring and Disposition - [125]
Li Y, Chen J, Gao Y et al.. “Comparative Safety of SGLT2 Versus DPP4 Inhibitors in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.” Diabetes therapy : research, treatment and education of diabetes and related disorders (2026). PMID: 41678006 ↗
L1aSR_MA_RCTCited in: Monitoring and Disposition - [126]
Hu Q, Fan Y, He P. “Islet function impairment outcomes of immune checkpoint inhibitors in cancer patients: a systematic review and meta-analysis.” Frontiers in immunology (2026). PMID: 41939914 ↗
L2aSR_OBSCited in: Monitoring and Disposition - [127]
Chiang YC, Dai DF, Chiu YW et al.. “Sodium-Glucose Cotransporter-2 Inhibitors and Acute Kidney Injury Risk: A Systematic Review and Meta-Analysis of Randomized Trials.” Kidney medicine (2026). PMID: 41767694 ↗
L2aSR_OBSCited in: Monitoring and Disposition - [128]
Oktavian P, Salma ZN, Harjono S et al.. “Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy to Insulin Pumps for Type 1 Diabetes: A Systematic Review and Meta-Analysis.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2026). PMID: 41621646 ↗
L2aSR_OBSCited in: Monitoring and Disposition - [129]
Balbaa E, Gadelmawla AF, Ibrahim A et al.. “Renal Protection at a Metabolic Cost: A Systematic Review and Meta-Analysis of Perioperative Use of Sodium-Glucose Cotransporter 2 Inhibitors.” Endocrinology, diabetes & metabolism (2026). PMID: 41721639 ↗
L2aSR_OBSCited in: Monitoring and Disposition - [130]
Zhang F, Wei L, Liu Y et al.. “Association between the lactate-to-albumin ratio and 28-day all-cause mortality in diabetic ketoacidosis patients: A retrospective cohort study utilizing the MIMIC-IV database.” PloS one (2026). PMID: 41818201 ↗
L2bCOHORTCited in: Monitoring and Disposition - [131]
Panic Zaric S, Vukomanovic V, Vukovic R et al.. “Case report: Takotsubo cardiomyopathy and cardiac arrest in a 9-year-old girl with new-onset diabetes presenting with diabetic ketoacidosis: the chicken or the egg?” Frontiers in endocrinology (2025). PMID: 41573196 ↗
L4CASE_REPORTCited in: Monitoring and Disposition, Special Populations - [132]
Gandecka-Pempera A, Naskręt D, Adamska A et al.. “Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report.” Frontiers in endocrinology (2025). PMID: 41127515 ↗
L4CASE_REPORTCited in: Monitoring and Disposition - [133]
Sweety S, Panda S, Das RR. “Balanced electrolyte solution vs isotonic saline in the resuscitation of children with diabetic ketoacidosis: A randomized controlled trial.” World journal of clinical pediatrics (2026). PMID: 41884024 ↗
L1bRCTCited in: Special Populations - [134]
Gao SY, Huang YG, Wang LB et al.. “Age-related heterogeneity of type 1 diabetes mellitus in children: a single-center retrospective study.” World journal of pediatrics : WJP (2026). PMID: 41455069 ↗
L2bCOHORTCited in: Special Populations - [135]
Rivetti G, Braile M, Di Sessa A et al.. “Acute Kidney Injury in Children with Polyuria: A Systematic Review.” Journal of clinical medicine (2026). PMID: 41517599 ↗
L2aSR_OBSCited in: Special Populations - [136]
Idrees H, Memon F, Alam R et al.. “Systematic Review and Meta-Analysis of Insulin Dose and Route of Administration Regimens for Diabetic Ketoacidosis in Children and Adolescents.” Journal of clinical medicine (2025). PMID: 41227190 ↗
L2aSR_OBSCited in: Special Populations - [137]
Pachapure S, Kandagal J, Revanasiddappa M et al.. “Acute Kidney Injury in Children with Type 1 Diabetes Mellitus Hospitalized for Diabetic Ketoacidosis: A Retrospective Study.” Journal of the ASEAN Federation of Endocrine Societies (2025). PMID: 41357044 ↗
L2bCOHORTCited in: Special Populations - [138]
Günbaş M, Büyükkaya Besen D, Dervişoğlu M. “The effect of one-year online counseling provided to mothers of children and adolescents with newly diagnosed type 1 diabetes on A1C and patient outcomes: A retrospective study.” Journal of pediatric nursing (2026). PMID: 41455371 ↗
L2bCOHORTCited in: Special Populations - [139]
Zhao S, Liu X, Tan P et al.. “Case report: Immune checkpoint inhibitor-induced fulminant diabetic ketoacidosis: a case-based review and considerations for immunotherapy discontinuation.” Frontiers in immunology (2025). PMID: 41635837 ↗
L4CASE_REPORTCited in: Special Populations - [140]
Calderon Martinez E, Saji SZ, Sámano Sánchez M et al.. “Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections for Glycemic Control in Pediatric Patients With Type 1 Diabetes Mellitus: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.” AACE endocrinology and diabetes (2026). PMID: 41938301 ↗
L2aSR_OBSCited in: Special Populations - [141]
Ali NM, Alhag MH, Mustafa AE et al.. “Prevalence, Clinical Profile, and Outcomes of Diabetic Ketoacidosis (DKA) in Pediatric ICU Patients in the Middle East: A Systematic Review and Meta-Analysis.” Cureus (2026). PMID: 41859577 ↗
L2aSR_OBSCited in: Special Populations - [142]
Natale P, Green SC, Tunnicliffe DJ et al.. “Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes.” The Cochrane database of systematic reviews (2025). PMID: 41263251 ↗
L2aSR_OBSCited in: Special Populations - [143]
Omar Salem Kanzwl SM, Alhajri AHM, Abdelbagi Mohammed YJ et al.. “A Comparative Effectiveness of Intravenous Fluids and Insulin Regimens in the Acute Management of Diabetic Ketoacidosis (DKA) and Hypoglycemia: A Systematic Review.” Cureus (2025). PMID: 41262789 ↗
L2aSR_OBSCited in: Special Populations - [144]
Convertino I, Lucenteforte E, Monzillo J et al.. “SodiuM glucose cotrANsporter-2 (SGLT-2) inhibitors in the treatment of type II DiAbetes in Tuscany: utiLizatiOn patteRns, and relatEd clinical use evaluation; the MANDALORE study protocol.” Frontiers in endocrinology (2026). PMID: 41948551 ↗
L5OTHERCited in: Special Populations - [145]
Ruprai B, Catania S, Berati V et al.. “Efficacy and Management of Automated Insulin Delivery Systems Perioperatively in Type 1 Diabetes - A Scoping Review.” Canadian journal of diabetes (2026). PMID: 41825832 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [146]
Hussain S, Tree T, Mathieu C et al.. “An international consensus on screening and monitoring early-stage type 1 diabetes: A roadmap to European implementation.” Diabetes, obesity & metabolism (2026). PMID: 41821267 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [147]
Lechsner P, Holl RW, Steger F. “Screening for diabetes mellitus type 1 in the pediatric general population: an ethical analysis.” European journal of pediatrics (2026). PMID: 41820768 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Prevention - [148]
Chaffin Z, Ghetti S, Tancredi D et al.. “Inflammatory profile of diabetic ketoacidosis in children with type 1 diabetes.” BMJ open diabetes research & care (2026). PMID: 41807017 ↗
L5OTHERCited in: Special Populations - [149]
Ward MC, Boucsein A, Zhou Y et al.. “Extended Use of Automated Insulin Delivery in Young People with Type 1 Diabetes and Elevated HbA1c: 52-Week Outcomes of the CO-PILOT Trial.” Diabetes technology & therapeutics (2026). PMID: 41784095 ↗
L5OTHERCited in: Special Populations - [150]
Mustafa OG, Haq M, Dashora U et al.. “Management of Hyperosmolar Hyperglycaemic State (HHS) in Adults: An updated guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care Group.” Diabetic medicine : a journal of the British Diabetic Association (2023). PMID: 36370077 ↗
L1cGUIDELINECited in: Prevention - [151]
Sharma A, Ali Baig S, Thayakaran R et al.. “Clinical characteristics and outcomes of diabetes-related ketoacidosis (DKA) in sodium-glucose co-transporter-2 inhibitor (SGLT2i) users with type 2 diabetes.” Diabetes, obesity & metabolism (2025). PMID: 40919651 ↗
L2aSR_OBSCited in: Prevention - [152]
Beccia C, McMorrow R, Donald A et al.. “Have interventions aimed at assisting general practitioners in facilitating earlier diagnosis of type 1 diabetes in children been successful in preventing acute complications? A systematic review.” BMJ open (2024). PMID: 39353690 ↗
L2aSR_OBSCited in: Prevention - [153]
Minerba E, Maines E, Quaglia N et al.. “Diabetes Awareness Campaigns to Prevent Ketoacidosis at the Diagnosis of Type 1 Diabetes: Efficacy on Multiple Outcomes and Predictors of Success: A Systematic Review.” Journal of personalized medicine (2024). PMID: 39728028 ↗
L2aSR_OBSCited in: Prevention - [154]
Alshehri NA, Alessa MS, Alrasheed AA et al.. “Role of Continuous Glucose Monitoring in Supporting Glycemic Control Among Adolescents with Type 1 Diabetes in Saudi Arabia: A Retrospective Study.” Healthcare (Basel, Switzerland) (2025). PMID: 40077058 ↗
L2bCOHORTCited in: Prevention - [155]
Takemura M, Ikemura K, Okuda M. “Factors and preventive strategies for perioperative euglycemic diabetic ketoacidosis in patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors: a retrospective study.” Journal of pharmaceutical health care and sciences (2025). PMID: 40855351 ↗
L2bCOHORTCited in: Prevention - [156]
Barth KE, Spottiswoode N, Hurabielle C et al.. “Clinical and biological heterogeneity of multisystem inflammatory syndrome in adults following SARS-CoV-2 infection: a case series.” Frontiers in medicine (2023). PMID: 37484839 ↗
L4CASE_REPORTCited in: Prevention - [157]
Haile HK, Fenta TG. “Magnitude, risk factors and economic impacts of diabetic emergencies in developing countries: A systematic review.” PloS one (2025). PMID: 39903717 ↗
L2aSR_OBSCited in: Prevention - [158]
Feleke SF, Dessie AM, Getachew ZD et al.. “Burden of diabetic ketoacidosis and its predictors among diabetic patients in Ethiopia: Systematic review and meta-analysis.” PloS one (2025). PMID: 39847589 ↗
L2aSR_OBSCited in: Prevention - [159]
Ahmed AAO, Mounfali MAA, Yassin T et al.. “Prevalence and patterns of diabetic ketoacidosis (DKA) among diabetic patients presenting to hospitals in northern state, Sudan: a cross-sectional study during the 2025 humanitarian crisis.” BMC endocrine disorders (2025). PMID: 41299380 ↗
L5OTHERCited in: Prevention - [160]
Sinatra N, Cuttone G, Geraci G et al.. “Correlation Between Hypophosphatemia and Hyperventilation in Critically Ill Patients: Causes, Clinical Manifestations, and Management Strategies.” Biomedicines (2025). PMID: 41153669 ↗
L5REVIEW_NARRATIVECited in: Prevention - [161]
Saygili M, Gollu G, Tekin Z. “Pandemic-driven healthcare disruptions and their disproportionate impact on patients with diabetes: evidence from Texas.” Frontiers in public health (2025). PMID: 41112649 ↗
L5OTHERCited in: Prevention - [162]
Tian B, Cao X, Cheng J et al.. “Aspiration pneumonia in diabetic ketoacidosis: a decade-long analysis of occurrence , associated risk factors and clinical outcomes in 530,700 US hospitalizations.” Diabetology & metabolic syndrome (2025). PMID: 41094594 ↗
L5OTHERCited in: Prevention - [163]
Wondie Y, Minwuyelet A, Bogale AD et al.. “Risk factors of diabetic ketoacidosis among patients with diabetes attending at public hospitals of East Gojjam Zone, Northwest Ethiopia: an unmatched case - control study.” BMC endocrine disorders (2025). PMID: 41039479 ↗
L5OTHERCited in: Prevention - [164]
Templeman EL, Ferrat LA, Parikh HM et al.. “Development and recalibration of a multivariable type 1 diabetes prediction model for type 1 diabetes across multiple screening studies.” BMC medicine (2025). PMID: 40691800 ↗
L5OTHERCited in: Prevention - [165]
Zhang B, Deng L. “Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety.” Frontiers in medicine (2025). PMID: 40665981 ↗
L5REVIEW_NARRATIVECited in: Prevention - [166]
Rewers M. “Health economic considerations of screening for early type 1 diabetes.” Diabetes, obesity & metabolism (2025). PMID: 40555704 ↗
L5REVIEW_NARRATIVECited in: Prevention - [167]
Bell KJ, Lain SJ. “The Changing Epidemiology of Type 1 Diabetes: A Global Perspective.” Diabetes, obesity & metabolism (2025). PMID: 40536127 ↗
L5REVIEW_NARRATIVECited in: Prevention - [168]
Besser REJ, Campbell F, Damazer K et al.. “UK best practice recommendations for children and young people <18 years with pre-stage 3 type 1 diabetes, on behalf of the British Society for Paediatric Endocrinology and Diabetes (BSPED).” Diabetic medicine : a journal of the British Diabetic Association (2025). PMID: 40988096 ↗
L1cGUIDELINECited in: Guidelines and Resources - [169]
Phillip M, Achenbach P, Addala A et al.. “Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes.” Diabetes care (2024). PMID: 38912694 ↗
L1cGUIDELINECited in: Guidelines and Resources - [170]
Phillip M, Achenbach P, Addala A et al.. “Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes.” Diabetologia (2024). PMID: 38910151 ↗
L1cGUIDELINECited in: Guidelines and Resources - [171]
Dhatariya KK. “The management of diabetic ketoacidosis in adults-An updated guideline from the Joint British Diabetes Society for Inpatient Care.” Diabetic medicine : a journal of the British Diabetic Association (2022). PMID: 35224769 ↗
L1cGUIDELINECited in: Guidelines and Resources - [172]
Priyambada L, Wolfsdorf JI, Brink SJ et al.. “ISPAD Clinical Practice Consensus Guideline: Diabetic ketoacidosis in the time of COVID-19 and resource-limited settings-role of subcutaneous insulin.” Pediatric diabetes (2020). PMID: 32935435 ↗
L1cGUIDELINECited in: Guidelines and Resources - [173]
. “ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus.” Obstetrics and gynecology (2018). PMID: 30461693 ↗
L1cGUIDELINECited in: Guidelines and Resources - [174]
Price HC, Ismail K. “Royal College of Psychiatrists Liaison Faculty & Joint British Diabetes Societies (JBDS): guidelines for the management of diabetes in adults and children with psychiatric disorders in inpatient settings.” Diabetic medicine : a journal of the British Diabetic Association (2018). PMID: 30152583 ↗
L1cGUIDELINECited in: Guidelines and Resources - [175]
Scott AR. “Management of hyperosmolar hyperglycaemic state in adults with diabetes.” Diabetic medicine : a journal of the British Diabetic Association (2015). PMID: 25980647 ↗
L1cGUIDELINECited in: Guidelines and Resources - [176]
Bismuth E, Bouche C, Caliman C et al.. “Management of pregnancy in women with type 1 diabetes mellitus: guidelines of the French-Speaking Diabetes Society (Société francophone du diabète [SFD]).” Diabetes & metabolism (2012). PMID: 22521040 ↗
L1cGUIDELINECited in: Guidelines and Resources - [177]
Savage MW, Dhatariya KK, Kilvert A et al.. “Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis.” Diabetic medicine : a journal of the British Diabetic Association (2011). PMID: 21255074 ↗
L1cGUIDELINECited in: Guidelines and Resources - [178]
Arima H, Iwama S, Inaba H et al.. “Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society.” Endocrine journal (2019). PMID: 31243183 ↗
L1cGUIDELINECited in: Guidelines and Resources - [179]
VanBaak KD, Nally LM, Finigan RT et al.. “Wilderness Medical Society Clinical Practice Guidelines for Diabetes Management.” Wilderness & environmental medicine (2019). PMID: 31753543 ↗
L1cGUIDELINECited in: Guidelines and Resources - [180]
Taylor S, Cannon M, Church D et al.. “iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats.” Journal of feline medicine and surgery (2025). PMID: 41224734 ↗
L1cGUIDELINECited in: Guidelines and Resources